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Abstract
A core pathological feature of AD is the over-production of reactive oxygen species (ROS),
which mediate oxidative stress in the brain. Peroxisomes play a crucial role in mitigating ROS
accumulation due to the presence of catalase, an antioxidant enzyme found within the organelle.
As the brain ages, progressive dysfunction of peroxisomes and decreased localization of catalase
into the organelle contributes to elevated ROS. A suitable therapy to address the increased
accumulation of ROS in AD has yet to be identified. Our team has engineered a recombinant
derivative of the antioxidant enzyme catalase (CAT-SKL) that specifically targets peroxisomes,
thereby providing powerful organelle-based antioxidant and anti-inflammatory effects. In the
present study, we aimed to (i) establish the packaging CAT-SKL into macrophage-derived
exosomes — endogenous membrane vesicles for the transport of proteins between cells — to
effectively target our therapeutic to cells undergoing oxidative stress while minimizing
degradation in the bloodstream, (ii) determine the safety and biodistribution in vivo, and (iii) assess
the protective effects of prophylactic intranasal administration of exosomes loaded with CAT-SKL
(exoCAT-SKL). CAT-SKL was packaged into macrophage-derived exosomes via sonication, and
loaded exosomes were purified using size exclusion chromatography or ultracentrifugation. Male
and female, control, and 3xTG AD transgenic mice were intranasally administered exoCAT-SKL,
and tissues of interest were investigated. The diffuse labelling of CAT- SKL in these mice's brains
supports the intranasal administration of exosomes as an effective delivery method to bypass issues
surrounding bioavailability, antigenicity, and the blood-brain barrier. Histopathological
assessments of the brain and off-target tissue demonstrated no toxicity. Further behavioural and
immunohistochemical analysis is required to determine whether exoCAT-SKL can prevent and
ameliorate pathological and behavioural outcomes in 3xTG AD mice.

Keywords: Alzheimer’s disease, Oxidative Stress, Drug delivery and toxicology, Exosomes,
Therapeutic antioxidants, Catalase
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Lay summary
This project investigated the use of nanosized vesicles called exosomes to carry and deliver
CAT-SKL, an antioxidant molecule, into a preclinical transgenic mouse model of Alzheimer’s
disease (AD). Human patients with AD demonstrate progressive dysfunction of peroxisomemediated lipid oxidation leading to excessive accumulation of reactive oxygen species (ROS).
CAT-SKL specifically targets these peroxisomes and provides antioxidant, anti-inflammatory and
anti-ageing effects. Intranasal administration of CAT-SKL loaded exosomes can penetrate the
brain, potentially preventing and ameliorating pathological, biochemical, and behavioural
outcomes. This project also provided further validation for the use of nanoparticles to deliver
therapeutics to the brain.
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Section 1: INTRODUCTION
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1.1 Alzheimer’s disease
Alzheimer's disease (AD) is a neurodegenerative disorder that causes a progressive decline
in a person's cognitive and behavioural abilities (Neugroschl and Wang, 2011). AD has a
devastating impact not only on the diagnosed individual but also on caregivers and healthcare
systems (Koca, Taşkapilioğlu and Bakar, 2017). In Canada, over half a million people are living
with AD, and the number of AD cases is expected to double in the next 15 years (Alzheimer's
Disease International, 2019). Globally, in 2006, an estimated 26.6 million people were living with
AD, and over 106 million cases are projected by 2050 (Brookmeyer et al., 2007). Symptoms of
AD begin with confusion, amnesia, and progress to severe cognitive impairments such as memory
and language deficits, and executive dysfunction (Förstl and Kurz, 1999; Humbert et al., 2010).
Eventually, the deterioration and loss of critical bodily functions such as the ability to swallow
cause severe complications and lead to death (Zanetti, Solerte and Cantoni, 2009). This
progression is variable as the typical life expectancy following diagnosis is between 3 and 9 years.
Currently, Canada is ill-equipped to manage the growing costs and lacks the infrastructure to
manage this public health crisis (Chambers, Bancej and Mcdowell, 2016). Understanding the
etiology and pathology of AD are essential first steps in combating the AD epidemic and reducing
the burden to healthcare resources.
AD can be categorized into early-onset and late-onset AD. Two universal hallmark
pathologies of the AD brain are extracellular β-amyloid (Aβ) plaque deposition and intracellular
aggregates of tau protein forming neurofibrillary tangles. As AD progresses, these two pathologies
are strongly linked to neuroinflammation, the loss of neurons and synapses, as well as the
enlargement of ventricles due to whole brain atrophy (Perl, 2010). Several genetic mutations have
been identified as the cause of the early-onset autosomal dominant form of AD. These mutations
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are found in the amyloid precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2)
(Piaceri, Nacmias and Sorbi, 2013). In particular, APP, PS1, and PS2 mutations affect the
processing of APP at γ-secretase or β-secretase cleavage sites. These mutations result in an
increased production of Aβ peptides leading to an increased accumulation of amyloid plaques
(Bhadbhade and Cheng, 2012; Kelleher and Shen, 2017). The majority of AD cases are not
categorized as early-onset. It is estimated that up to 70% of cases are of the late-onset category
(Piaceri, Nacmias and Sorbi, 2013). The most prevalent genetic risk factor for developing lateonset AD is the apolipoprotein E (ApoE) 4 allele (Vanitallie, 2013; Safieh, Korczyn and
Michaelson, 2019). ApoE plays an essential role in cholesterol transport and regulating lipid
metabolism in the brain (Huang and Mahley, 2014). Possession of the ApoE 4 allele results in
reduced Aβ clearance by the glymphatic system and astrocytes, one of the brain's glial cell types.
As such, individuals homozygous for the ApoE 4 allele have up to 12 times the risk of developing
AD (Michaelson, 2014; Fernandez et al., 2019). The etiology of AD remains convoluted due to
the complexity of the disease as it involves a combination of protein misfolding and aggregation,
neuroinflammation, and oxidative stress, amongst other environmental factors (Jiang et al., 2013).
Although genetics convey additional risks for affected individuals, the most significant
known risk factor for AD is age (Guerreiro and Bras, 2015). The majority of AD patients are older
than 65, with a higher incidence among older populations. Suggested practices by the National
Institute of Health to prevent AD or delay the age of onset include: managing comorbidities such
as diabetes and high blood pressure, increasing physical activity, maintaining a healthy balanced
diet, and staying cognitively stimulated (National Institute of Health, 2018). These
nonpharmacologic measures are also crucial in the management of symptoms as a cure for AD
does not yet exist (Dharmarajan and Gunturu, 2009). Available treatments that target Aβ
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production, aggregation, or clearance have not led to curative clinical outcomes (Yiannopoulou
and Papageorgiou, 2013; Mehta et al., 2017). The most common drug option, acetylcholinesterase
inhibitors, have been shown to slow the progression of the disease but often lead to off-target
toxicity such as hepatotoxicity and adverse gastrointestinal symptoms (Ali et al., 2015). Other
drugs such as N-Methyl-D-aspartate inhibitors are better tolerated however are typically prescribed
for advanced stage AD with modest benefits in patients (Olivares et al., 2013). Developing
potential medications that are both safe and effective requires further knowledge of how AD
disrupts the brain.

1.2 Anatomical brain areas associated with AD
As AD progresses, different areas of the brain are affected, highlighting the connections
between anatomical and cognitive changes (Raskin et al., 2015). In earlier stages of the disease,
cells of the hippocampus begin to degenerate, causing deficits in memory and learning. Significant
reductions of neurons are seen in the CA1 and less so in CA3 hippocampal areas of patients with
AD (Padurariu et al., 2012), which may partially explain the loss of memory seen in AD patients.
The hippocampus is an especially vulnerable and essential brain area strongly tied to the cognitive
impairments accompanied with AD (Halliday, 2017).
In the moderate AD stage, cerebral cortical atrophy occurs, causing severe behavioural
deficits and the inability to perform simple tasks (Bakkour et al., 2013). Post-mortem examination
of AD brains reveals a reduction in total brain size and weight, with widened sulci indicating the
loss of cortical interneurons and neurotransmitter pathways (Whitwell, 2010). In human and rodent
models of AD, a loss of cholinergic neurons is observed in the basal forebrain, while noradrenergic
degeneration is observed in the locus coeruleus (Mufson et al., 2008). While this phenomenon is
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observed in the moderate stage for humans, it is not replicated in rodent models of AD until later
stages of the disease. Instead, preclinical moderate stage AD mouse models feature
neuroinflammation marked by microgliosis, astrocytosis, and deposits of amyloid plaques (Saito
and Saido, 2018).
Findings in rodents show that early-stage neuroinflammation and white matter etiologies
contribute to AD progression in addition to grey matter etiologies. In particular, white matter
inflammation and demyelination have been reported in the corpus callosum and the internal
capsule preceding Aβ plaques, perhaps driving Aβ production (Raj et al., 2017). Developing drugs
to target the hippocampus and white matter inflammation early on in AD progression may prevent
or reduce cognitive decline.

1.3 Beta-amyloid, amyloid cascade hypothesis and neuroinflammation
The amyloid cascade hypothesis has been the most prominent AD research hypothesis
since the early 1990s (Hardy and Allsop, 1991; Selkoe, 1991; Hardy and Higgins, 1992; Ricciarelli
and Fedele, 2017). The hypothesis posits that excessive Aβ causes AD and triggers a cascade of
downstream symptoms and pathologies such as cognitive decline, progressive neuronal injury,
neuroinflammatory responses, and oxidative injury (Barage and Sonawane, 2015). Aβ is derived
from APP, which is ubiquitously expressed but predominantly in the central nervous system (CNS)
(Puig and Combs, 2013). APP is a highly conserved transmembrane protein; however, the exact
function of APP is not fully understood. It is accepted that it plays a role in cell growth, cell
survival, and synapse physiology (Bhadbhade and Cheng, 2012). The production of Aβ is a normal
cellular process and begins with sequential cleavage of APP by two intramembranous
endoproteases, β-secretase and γ-secretase. β-secretase cleaves APP into a protein that is 99 amino
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acids in length, and γ-secretase subsequently cleaves the protein at the γ-cleavage site to 38 - 42
amino acids (Chow et al., 2010; Macleod et al., 2015). A third endoprotease, α-secretase, can also
cleave APP; however, the resulting peptide (sAPP- α) does not lead to Αβ formation (Zhang et al.,
2011). Ninety-percent of the cleaved APP is 40 amino acids in length (Aβ40), and the less abundant
cleaved APP is 42 amino acids in length (Aβ42) (Qiu et al., 2015). The two isoforms of Aβ differ
by two amino acids, isoleucine and alanine, with Aβ42 more highly related to AD pathogenesis
compared to Aβ40. Aβ42 demonstrates increased aggregation and fibril formation, which
contribute to amyloid plaques formation (Cline et al., 2018). Aβ42 has also been reported to have
higher cellular toxicity, and clinical experiments suggest mutations causing AD result in an
increase in the Aβ42 to Aβ40 ratio (Lehmann et al., 2018). Both isoforms of Aβ can be found in
the cerebrospinal fluid (CSF) with 50-70% in the form of Aβ40 and roughly 10% as Aβ42 in
healthy adults. Aβ37, Aβ38, Aβ39, and Aβ43 isoforms make up the remaining Aβ found in the
CSF (Qiu et al., 2015). An increased ratio of CSF Aβ42 to Aβ40 in combination with CSF
concentrations of tau species has been used as a diagnostic tool of AD (Hansson et al., 2019).
Several mechanisms exist to catabolize Aβ42 for degradation or transport out of the CNS.
Enzymes such as neprilysin and insulin degrading enzyme play essential roles in the extracellular
degradation of Aβ while transport proteins called low-density lipoprotein receptor-related protein
1 are responsible for transcellular transport of Aβ across the blood-brain-barrier (BBB) (Deane et
al., 2009; Grimm et al., 2013). The amyloid cascade hypothesis proposes that neurodegeneration
arises when Aβ is overproduced, and the clearance and degradation are reduced, causing the
buildup of Aβ (Barage and Sonawane, 2015).
The hydrophobic nature of Aβ42 enables the formation of β sheet protein structures, and
other structures such as fibrils and oligomers (Baldassarre et al., 2017). Aβ oligomers are reported
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to be more toxic than Aβ fibrils and cause oxidative damage, cell membrane disruption, and induce
neural cell apoptosis pathways (Verma, Vats and Taneja, 2015; Sengupta, Nilson and Kayed,
2016). In addition, Aβ triggers the activation of inflammatory responses marked by reactive
microglia activation and reactive astrocytosis (Hensley, 2010). Microglia and astrocytes respond
to insults caused by Aβ by transitioning from a ramified form to an active phagocytic form and
migrating to the site of injury. The number of activated microglia and astrocytes has been shown
to increase in relation to the amount of Aβ plaques (Bolmont et al., 2008). Scavenger receptors on
microglia and its phagocytic nature allow for modest Aβ engulfment, but the activated microglia
phenotype is accompanied by the release of pro-inflammatory cytokines and ROS (Doens and
Fernández, 2014). Aβ deposits are difficult to remove, and chronic microglial activation as seen in
AD leads to a 'frustrated phagocytosis' phenotype, causing an extended release of inflammatory
molecules such as interleukin-1β, interleukin-6, and tumour necrosis factor-α (Majerova et al.,
2014; Wang et al., 2015). This phenomenon causes a toxic environment for neurons and also leads
to neurotoxic injuries such as demyelination, synaptic dysfunction, and ultimately neuron death
(Lull and Block, 2010). Therefore, exploring neuroinflammation is a promising strategy that may
lead to novel approaches and ameliorate the burden of AD.

1.4 Reactive oxygen species and oxidative stress in Alzheimer’s disease
Oxidation and reduction (redox) reactions in living organisms are utilized in fundamental
processes and are necessary for overall health. An unavoidable consequence of redox reactions is
the production of ROS (Zuo et al., 2015). ROS is an umbrella term that includes active oxygencontaining compounds such as hydrogen peroxide (H2O2), superoxide anion (O2- ), hydroxyl
radical (OH-), amongst other radicals. ROS is primarily produced in the mitochondria through the
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electron transport chain and the oxidative phosphorylation pathway (Ray, Huang and Tsuji, 2012).
In particular, H2O2 is continuously produced by the mitochondria and accounts for 40% of the
H2O2 in the cytosol (Boveris and Cadenas, 2001). Compared to other ROS, H2O2 is a stable
molecule that can diffuse easily between cells and react with free metals (Groeger, Quiney and
Cotter, 2009). The Fenton reaction occurs when H2O2 reacts with iron or copper to produce the
damaging hydroxyl radical (Winterbourn, 1995).

Fe2+ + H2O

® Fe3+ + [H2O2-]

®

OH + OH-

ROS are signalling messengers that play a role in normal cellular function (Dröge, 2002),
but become problematic when they are chronically present. ROS modulate cell cycle pathways
and maintain the balance between cell proliferation and apoptosis at normal levels (Finkel, 2011).
ROS also play an important role in the immune system as cells utilize ROS to undergo the
phagocytosis process and fight against foreign bodies (Dupré-Crochet, Erard and Nüβe, 2013).
Neutrophils, monocytes, macrophages and microglia are significant cellular sources of
ROS. These cells utilize cellular enzymes such as nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase to secrete ROS and serve as both a protective and inflammatory mechanism
(Haslund-Vinding et al., 2017). Toll-like receptor-4 on the surface of microglia is activated by the
binding of foreign bodies to NADPH oxidase triggering downstream ROS production to
breakdown pathogens (Fiebich et al., 2018). However, ROS can be extremely harmful if produced
in excess of normal physiologic levels (Zuo et al., 2015). Downstream effects due to the
overproduction of ROS include lipid peroxidation, nucleic acid damage, protein oxidation, and
enzyme inhibition, all leading to cellular dysfunction and cell death (Mylonas and Kouretas, 1999;
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Cadet and Richard Wagner, 2013; Sharman, 2016). Lipid peroxidation occurs when ROS targets
polyunsaturated fatty acids of membrane phospholipids in the brain (Sultana, Perluigi and
Butterfield, 2013). These reactions lead to the production of highly reactive aldehydes such as 4hydroxy-2-nonenal and malondialdehyde. Reactive aldehydes are strong electrophiles and react
with amino acids and nucleic acids, leading to the inhibition of DNA, RNA, cell membrane
function, and protein synthesis (Matveychuk et al., 2011).
Antioxidants are endogenous molecules that function to counteract free radicals and
neutralize oxidants by breaking them down into less reactive molecules (Pham-Huy, He and PhamHuy, 2008). However, excessive ROS levels can overwhelm the body’s antioxidant mechanisms,
resulting in oxidative stress. Increased oxidative stress is linked to ageing and disease (Liguori et
al., 2018). The over-production of ROS can be attributed to several mechanisms such as
mitochondrial electron-transport chain dysfunction, overwhelmed antioxidant mechanisms,
microglia activation pathways, amyloid deposition, and metal abnormalities (Valko et al., 2007;
Su et al., 2008). These primary sources of ROS imbalances have been implicated in both the
pathogenesis of AD as well as an outcome of the disease (Wang et al., 2014; Manoharan et al.,
2016). Aβ42 induces oxidative stress in the brain by binding with transition metal ions such as iron
and copper generating H2O2 and other hydroxyl radicals (Huang et al., 1999). Markers of
increased lipid peroxidation have also been correlated with amyloid plaques deposition (Praticò et
al., 2001). More research is required to characterize oxidative sources and the cellular
consequences of excessive ROS. This is of particular importance since the regulation of ROS
through cellular antioxidant systems is crucial for maintaining cell viability and ultimately organ
function in patients with AD.
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1.5 Peroxisomes and cellular mechanisms of ROS mitigation
Mammalian peroxisomes are essential organelles that perform oxidation reactions involved
in the breakdown of amino and fatty acids to produce metabolic energy (Cooper, 2000).
Peroxisomes are a significant source of oxidative metabolism comprising up to 20% of total
cellular oxygen consumption and oxidative stress (Wanders, Waterham and Ferdinandusse, 2016).
Within the nervous system, peroxisomes are found in all neural cell types such as neurons,
microglia, astrocytes, and oligodendrocytes. Peroxisomes of the nervous system are involved in a
variety of catabolic and anabolic reactions, including the biosynthesis of lipids, critical for the
formation of myelin and membrane processes of oligodendrocytes (Baes and Aubourg, 2009). A
harmful consequence of these oxidation reactions is the production of H2O2. The primary source
of H2O2 produced in peroxisomes occurs through the β-oxidation of fatty acids (Bonekamp et al.,
2009). This catabolic process oxidizes fatty acids into acetyl-CoA subunits; however, the highenergy electrons that are generated are not coupled to a respiratory chain destined for ATP
synthesis like those seen in the mitochondria. Instead, these electrons are coupled to oxygen
reduction reactions to form reactive H2O2 in turn upsetting the cellular redox balance, and
damaging DNA, proteins and lipids (Mylonas and Kouretas, 1999).
Peroxisomes contain many antioxidant enzymes that combat the effect of ROS, including
superoxide dismutase, peroxiredoxin, epoxide hydrolase, and catalase (Fransen et al., 2012).
Catalase is a 62 kDa enzyme that plays a critical protective role because it catalyzes H2O2 back
into water and oxygen (Schrader and Fahimi, 2006).

2 H2 O2

Catalase
®
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2 H 2 O + O2

Like all other peroxisomal matrix proteins, endogenous catalase is transcribed in the
cytosol and targeted to peroxisomes through the use of 4 amino acid residues at its carboxy
terminus, lysine-alanine-asparagine- leucine (-KANL), making up a peroxisome-targeting signal
sequence (PTS1) (Sheikh et al., 1998). The peroxisomal targeting signal type 1 receptor (PEX5p)
recognizes the targeting sequence on catalase leading to internalization of the enzyme for
H2O2 homeostasis (Terlecky, Koepke and Walton, 2006). These protective antioxidant systems
can be overwhelmed by ageing, cellular disturbances and peroxisomal dysfunction.
In cell culture models of ageing, the serial passaging of cells demonstrated decreased
catalase import into peroxisomes resulting in increased oxidative stress and cell senescence
(Koepke et al., 2007). Some diseases, such as the rare congenital Zellweger syndrome, are marked
by PEX5p mutations leading to deficient catalase import and excessive H2O2 buildup (Berger et
al., 2016). Peroxisomal dysfunction contributes to the pathogenesis of a variety of other diseases,
including cancer, diabetes, and AD (Cipolla and Lodhi, 2017). It is clear that peroxisomes and
catalase enzyme function as mediators of H2O2 metabolism. Additional research is required to
understand how this peroxiosomal pathway can potentially contribute to AD prevention. The
effectiveness of drugs that specifically target peroxisomes and H2O2 accumulation remains to be
determined.

1.6 Targeted antioxidant CAT-SKL
One of the major limitation of endogenous catalase is that the residues that make up its
PTS1 functionally deteriorate as cells age (Koepke et al., 2007). Due to this deterioration, strategies
have been previously developed to improve the shuttling of catalase to peroxisomes. The
engineered catalase (CAT-SKL, United States patents 7601366 and 8663630) used in this study
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replaces the -KANL terminus with a serine-lysine-leucine (-SKL) sequence to increase
peroxisomal targeting, thereby allowing for higher enzymatic metabolism of H2O2 (Koepke et al.,
2007; Giordano et al., 2015; Nell et al., 2017). The -SKL sequence is a more efficient peroxisome
targeting signal for importing proteins compared to the -KANL sequence and even functions when
PEX5p receptors are mutated (Koepke et al., 2007). CAT-SKL is effective in mitigating oxidative
stress in several in vitro and in vivo studies. Subcutaneous injections of CAT-SKL improved
subnormal intraretinal uptake of manganese and reduced oxidative liver damage in diabetic mice
(Giordano et al., 2015). CAT-SKL also protected against Aβ induced neurotoxicity and oxidative
stress in cultured primary cortical/hippocampal neurons (Giordano et al., 2014; Nell et al., 2017).
These pre-clinical studies suggest that CAT-SKL holds potential as a new therapeutic approach to
address the increased accumulation of ROS in disorders such as Parkinson’s and AD (Valko et al.,
2007; Price, Terlecky and Kessel, 2009; Cipolla and Lodhi, 2017; Nell et al., 2017). However,
the use of therapeutic antioxidants such as CAT-SKL has been hindered by physiological barriers
such as degradation of the antioxidant before reaching its cellular target (Moosmann and Behl,
2002). In addition, exogenous CAT-SKL alone has not been shown to penetrate the BBB.
Identifying a delivery system to effectively cargo CAT-SKL to the brain is essential to investigate
its protective effects in neurodegenerative diseases.

1.7 Blood-brain barrier and the intranasal delivery pathway – function and potential
The BBB is a unique microvasculature system that supports the CNS allowing for strict
regulation of transport of molecules between the blood and the brain. The restrictive nature of the
BBB is due to its anatomical architecture. A monolayer of polarized endothelial cells makes up
the walls of the blood vessels (Serlin et al., 2015). These cells are securely sealed to each other by
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a network of proteins, including claudins and occludins, to form tight junctions (Luissint et al.,
2012). Supporting connective tissue cells called pericytes on the abluminal (brain facing) surface
wrap the endothelial cells and play a role in endothelial proliferation and migration (Liu et al.,
2012). Astrocytes extend their cellular processes to sheath the entire endothelial cell border to
regulate the BBB permeability and blood flow. This barrier acts to protect the brain from foreign
bodies and other circulating pathogens (Daneman and Prat, 2015). The breakdown of the BBB
causes disease pathologies and is observed in severe neurological diseases such as Parkinson’s
disease, amyotrophic lateral sclerosis and AD (Sweeney, Sagare and Zlokovic, 2018). Although
the BBB serves a crucial function in maintaining the brain's protected environment, its selective
nature can become a limiting factor when designing potential therapeutics. Therefore the BBB is
a major barrier that must be addressed in order to evaluate the efficacy of candidate therapies
(Ballabh, Braun and Nedergaard, 2004).
One approach to penetrate the BBB in treating neurodegenerative diseases is to implement
the intranasal delivery of therapeutics (Erdő et al., 2018). Intranasal delivery utilizes both
intracellular and extracellular pathways to the brain. The extracellular route directly connects from
the nasal cavity to the brain and begins with crossing the nasal epithelium. The nasal epithelium is
composed of diverse cells connected by tight junctions more permissible than that of the BBB
(Yang et al., 2017). Lipophilic molecules can freely pass through these tight junctions, while
hydrophilic molecules diffuse through the tight junctions based on their size. Once the drug has
passed through the nasal epithelium, drugs are transported through the subarachnoid space of the
brain and directly into the CSF. The intracellular route employs the olfactory and trigeminal
nerves. It begins with endocytosis of the drug by olfactory sensory cells and subsequent axonal
transport to their synaptic clefts in the olfactory bulb. The drug is further exocytosed, and
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surrounding neurons repeat the neuronal translocation to other brain regions. Extracellular
transport of drugs is much faster than intracellular transport and is the main pathway used in
intranasal administration (Crowe et al., 2018a). While the intranasal route offers direct and rapid
access of lipophilic molecules to the brain, issues regarding the stability of drug delivery remain.
Targeting exogenous CAT-SKL through the nasal epithelium is impeded by protein degradation
and the enzymes' hydrophilic outer surface (Domínguez, Sosa-Peinado and Hansberg, 2010;
Pharmaceu Sci, Shah and Shao, 2017). The use of a lipophilic nanodelivery system that can protect
CAT-SKL from degradation would allow for both efficient and targeted delivery of CAT-SKL to
the brain (Li et al., 2017).

1.8 Exosomes and their potential as therapy delivery tools
Recent research into extracellular vesicles has garnered much attention and suggests a more
significant physiological role than previously recognized. Almost all eukaryotic cells produce
extracellular vesicles as a method of cell-to-cell communication (Tetta et al., 2013). Extracellular
vesicles carry biological cargo, including proteins, and nucleic acids, which are often taken up by
surrounding cells or transported through the circulatory system to distant cells (Margolis and
Sadovsky, 2019). Proteins and nucleic acids released from exosomes are able to carry out various
functions such as modulating cellular function and gene expression (Yáñez-Mó et al., 2015; Iraci
et al., 2016; Jiang and Gao, 2017).
Exosomes are unique, nanosized extracellular vesicles, ranging from 30 nm to 150 nm in
size (Théry et al., 2006). Exosomes originate from endosomes, which are internal invaginations
(endocytosis) of the cell plasma membrane (Zhang et al., 2019). Endosomes undergo a maturation
process from early through to late endosomes via interactions with the Golgi complex, where they

14

become increasingly acidic. During the late endosome stage, intraluminal vesicles form, and the
late endosome migrates towards the plasma membrane (Scott, Vacca and Gruenberg, 2014). These
intraluminal vesicles are contained within the late endosome until fusion occurs between the late
endosome membrane and the plasma membrane, where they are subsequently released as
exosomes into the extracellular space. Alternatively, exosomes can be transported for degradation
in lysosomes before reaching the plasma membrane (Zhang et al., 2019). Exosome membranes
have similar bilipid composition to that of the plasma membrane with additional lipids added from
the Golgi complex. The enriched lipid composition of exosomes increases their stability during
transport and allows for passage through membranes such as the BBB (Li et al., 2017). Once an
exosome reaches its target cell, it can be internalized by several potential mechanisms, including
receptor-dependant binding, direct fusion, and phagocytosis (McKelvey et al., 2015).
The innate ability of exosomes to permeate biological barriers with low immunogenicity
and toxicity while acting as agents of cellular communication offers a potential strategy to deliver
biologics of interest into cells (Barile and Vassalli, 2017; Jiang and Gao, 2017). Several methods
have been successfully implemented to load exogenous cargo into exosomes allowing for the
targeted cellular delivery (Zhuang et al., 2011; Tetta et al., 2013; Qu et al., 2018; Pomatto et al.,
2019; Zhang et al., 2019). Low loading capacity has been demonstrated from the passive
incubation of exosomes with the selected cargo. Hydrophobic drugs can diffuse through the lipid
membrane of exosomes along the concentration gradient (Zhuang et al., 2011; Haney et al., 2015).
Other passive techniques include treating cells with drugs and collecting their secreted exosomes
loaded with the drug (Pascucci et al., 2014). Mechanical methods have also been implemented to
load exosomes actively. Haney et al. demonstrated that the permeabilization of macrophagederived exosomes with saponin and sonication techniques provide high loading efficiency (Haney
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et al., 2015). In addition, techniques such as electroporation, freeze-thaw cycles, membrane
permeabilizers have been used to load exosomes with small drug molecules and miRNA (Luan et
al., 2017; Pomatto et al., 2019).
The biodistribution of systemically administered exogenous exosomes is similar to other
therapeutics such that accumulation primarily occurs in the liver, kidney, and spleen. Exosomes
have low immunogenicity and are efficiently excreted in the bile, renal system, and circulating
phagocytic cells (Lai et al., 2014). In vivo neuroimaging studies using nanoparticle tracking
technology have indicated that intranasal administration of exosomes efficiently penetrates the
BBB and demonstrates superior brain accumulation compared to intravenous administration
(Betzer et al., 2017). Zhuang et al. showed that intranasal administration of exosomes loaded with
curcumin was up-taken by microglia while Haney et al. demonstrated that intranasal administration
of exosomes loaded with catalase can effectively be delivered to neurons of mice as a
neuroprotective method against Parkinson’s disease (Zhuang et al., 2011; Haney et al., 2015).
Using macrophage-derived homologous exosomes of the same species as a delivery tool allows
for biologics to overcome barriers such as biodistribution, antigenicity, and the BBB. These
physiological hurdles have historically limited the therapeutic potential of proteinaceous reagents
in neurodegenerative diseases such as AD.

1.9 3xTG AD mouse model
There are numerous animal models to choose from to study AD, each with a distinct set of
AD pathophysiology. Most commonly used are transgenic rodents that foster characteristic ADrelated genetics. These genes are either disease-causing or serve as increased risk factors and
include APP, tau, PS1, and ApoE (Hall and Roberson, 2012). Although any single model cannot
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completely recapitulate AD pathology, mouse models conserve many of the mammalian genetic
and physiological characteristics observed in humans. Mice are a cost-effective reductionist
system that enables experimental manipulation in preclinical testing to develop new drugs
(Perlman, 2016). The model selected for this thesis was the 3xTG-AD mouse line, which combines
three mutant transgenes. The first is the human APP gene carrying the Swedish mutation. The APP
Swedish double mutations cause two amino acid substitutions (lysine to asparagine and methionine
to leucine) adjacent to the β-secretase site of APP. These mutations have been reported to increase
total Aβ levels (Haass et al., 1995). Mice carrying the APP Swedish mutations such as the 3xTGAD mouse line accumulate high levels of both soluble and insoluble Aβ and develop amyloid
pathology (Giménez-Llort et al., 2013). The second mutation involves the M146V mutation of
presenilin, a gene that encodes proteins required for the catalytic subunit of γ-secretase. Two
hypotheses surround how presenilin mutations lead to neurodegeneration and cognitive
impairments in AD. The amyloid hypothesis proposes that presenilin mutations increase the
production of Aβ42 or the Aβ42 to Aβ40 ratio, thus leading to increased amyloid plaque
deposition. The presenilin hypothesis proposes that presenilin mutations cause the loss of
presenilin function and reduces essential functions in learning, memory and neuronal survival
(Elder et al., 2010; Kelleher and Shen, 2017) The third and final mutation characterizing this
mouse model is the P301L mutation of human tau. (Sterniczuk et al., 2010). Tau mutations cause
the changes in tau protein splicing, phosphorylation state, and interactions with tubulin leading to
prominent neurofibrillary tangles found in AD patients (Goedert, 2005). Tau mutations themselves
do not cause AD, and their role in AD pathology is unclear. Current research shows that reducing
tau pathology has been linked to improving cognitive impairment in learning and memory (Iqbal
et al., 2010). Overall, these findings suggest that combining tau mutations with APP and PS1
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mutations provide an aggressive mouse phenotype with a combination of AD pathologies that
strongly mimic what is seen in human AD patients (Hall and Roberson, 2012).
The AD-like pathology of 3xTG-AD mice has been well described in previous studies.
These mice express human APP within the pyramidal cell layer of the hippocampus as early as
two months of age (Belfiore et al., 2019). The three transgenes cause 3xTG-AD mice to first
develop extracellular Aβ deposition and tau pathology at six months of age (Oddo et al., 2003;
Belfiore et al., 2019). Neuroinflammation marked by microglia activation in the hippocampus is
also evident in these mice as early as six months and increases with age (Belfiore et al., 2019).
Behaviour deficits have also been reported in 3xTG-AD mice at 6.5 months of age, as indicated
by spatial and memory deficits in the Barnes maze (Stover et al., 2015). Morris water maze testing
has shown differences in learning and memory in 6-month-old 3xTG mice compared to control
B6129FS mice (Stimmell et al., 2019). These findings highlight the utility of the 3xTG mouse
model due to the presentation of pathological and cognitive features reminiscent of human AD.

1.10 Rationale
Excess production of ROS, causing oxidative stress in the brain, is a core pathological
feature of AD (Valko et al., 2007). The use of non-specific antioxidants treatments has led to
inconsistent results due to physiological barriers common in human subjects and preclinical
models of AD. These barriers include the degradation of therapeutics in the blood and the
inability of candidate agents to cross the BBB to penetrate the brain (Moosmann and Behl,
2002). Current research has indicated that the dysfunction of peroxisomes, a cellular organelle,
contributes to this increase in harmful ROS (Cipolla and Lodhi, 2017). Peroxisomes play a
crucial role in ROS homeostasis balancing the production of H2O2 from β-oxidation of fatty
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acids with antioxidant functions of the enzyme catalase, which is active within the organelle
(Bonekamp et al., 2009). As the brain ages, progressive dysfunction of peroxisomes and
decreased localization of catalase into the organelle contributes to elevated ROS contributing to
the oxidative stress response in AD (Cheignon et al., 2018). This phenomenon has also been
observed in preclinical rodent models of AD. In particular, the 3xTG AD mouse used in the
present study has elevated levels of PMP70, a peroxisomal population marker, as early as 3
months of age reflecting the need for more efficient fatty acid β-oxidation. (Fanelli et al., 2013).
Increased markers of lipid peroxidation and oxidative stress are also observed in 3xTG AD mice
prior to traditional neuropathological hallmarks indicating the necessity for antioxidant therapy
at the early stages of AD (Resende et al., 2008). The engineered CAT-SKL used in our lab can
target this early AD pathology by effectively targeting peroxisomes and providing organellebased antioxidant, anti-inflammatory effects (Koepke et al., 2007; Giordano et al., 2014; Nell et
al., 2017).
A major obstacle with using CAT-SKL as a therapeutic is finding a method to efficiently
and safely deliver the enzyme to the brain while minimizing off-target effects. We proposed that
packaging CAT-SKL into exosomes could overcome this obstacle (Iraci et al., 2016). The use of
exosomes is a promising delivery method as it can cross the BBB, thereby delivering therapeutics
to cells of the CNS (Betzer et al., 2017; Li et al., 2017). Previous work by Haney et al. also
demonstrated that exosomes loaded with endogenous catalase decreased neuroinflammation and
increase neuronal survival in a mouse model of Parkinson’s disease (PD) (Haney et al., 2015).
Early stages of PD and AD exhibit similar pathologies such as microglia activation, excessive
secretion of ROS, and lower levels of antioxidant enzymes (Xie et al., 2014). Therefore, exosomemediated delivery of CAT-SKL is an intuitive strategy to target ROS in 3xTG AD mice.
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1.11 Hypothesis and aims
Overarching Thesis Hypothesis:
Intranasal administration of exoCAT-SKL will penetrate the BBB and provide non-toxic,
targeted antioxidant protection in mice.
Aim 1:
Demonstrate that intranasal administration of exoCAT-SKL can penetrate the BBB, assess the
brain biodistribution, and determine potential toxicity in young healthy mice.
Aim 2:
Assess the protective effects of prophylactic intranasal administration of exoCAT-SKL using
pathological, biochemical, and behavioural outcomes in control B6129FS and 3xTG AD mice.
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Section 2: METHODS
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2.1 Isolation of naïve exosomes and biotinylated catalase-SKL (bCAT-SKL)
Naïve exosomes from Raw 264.7 macrophages were collected and isolated using gradient
centrifugation and were provided by our collaborators Dr. Batrakova (UNC Eshelman School of
Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA). The preparation
and purification of bCAT-SKL and CAT-SKL was provided by the Shilton laboratory (Schulich
School of Medicine and Dentistry, Western University, London, ON, CA). The methods used to
isolate exosomes are previously described by Haney et al. (Haney et al., 2015). The genetic
reengineering of the catalase enzyme and purification of bCAT-SKL or CAT-SKL is as previously
described (Koepke et al., 2007).

2.2 ExoCAT-SKL preparation
A sonication technique was implemented to incorporate biotinylated CAT-SKL (bCATSKL) into exosomes. Naïve exosomes isolated from Raw 264.7 macrophages were diluted in
phosphate-buffered saline (PBS) to a concentration of 0.15 mg/mL exosome protein. A bCATSKL solution of 0.5 mg/mL was prepared. 250 μL of exosomes solution was combined with 125
μL of bCAT-SKL to achieve a final concentration of 0.1 mg/mL of total protein. This bCAT-SKL
and exosome mixture was then sonicated for six cycles of 4 seconds pulse and 2 seconds pause
(output power 9 watts – level 3), chilled on ice for 2 minutes, and sonicated again for six cycles of
4 seconds pulse and 2 seconds pause (Sonic Dismembrator Model 100, Fisher Scientific). The
sonicated mixture was then chilled on ice for 5 minutes, followed by a 37 °C water bath for 10
minutes, and 30 minutes at room temperature. The bCAT-SKL loaded exosomes (exoCAT-SKL)
were subsequently purified from unbound bCAT-SKL in solution by gel-filtration/size exclusion
chromatography with Sepharose CL-6B column (Sigma-Aldrich) or the Optima MAX-XP
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Benchtop Ultracentrifuge at 50 k RPM for 70 minutes using an MLA130 rotor at 4 oC. (Beckman
Coulter, California, USA). A total of 24 fractions of 1 mL each were collected from the gelfiltration chromatography column. For exoCAT-SKL purified using ultracentrifuge methods, the
supernatant from the ultracentrifuge solution was replaced with 0.1 M phosphate buffer solution
(PBS) and spun down again at 50 k RPM for 70 minutes at 4 oC. The remaining exoCAT-SKL
pellet was resuspended in 0.2 M sucrose solution. ExoCAT-SKL purified by ultracentrifuge was
stored at -80 oC for up to 5 weeks and underwent one freeze-thaw cycle before use. Gel-filtration
and western blot techniques, as described above, were implemented to confirm successful
ultracentrifuge purification and activity following one freeze-thaw cycle. A flowchart depicting
the methods of exosome loading of catalase-SKL and purification of exoCAT-SKL is displayed in
figure 1.
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Figure 1. Flowchart depicting methods of exosome loading of CAT-SKL and purification.
250 uL of exosome stock (0.15 mg/ml) is sonicated with 125 uL of 0.5mg/mL CAT-SKL. Two
methods of purification of loaded exoCat-SKL from free CAT-SKL are implemented: 1) by gel
Filtration and 2) by ultracentrifugation. Loading of exosomes is verified via BCA and H2O2
decomposition assays, and Western Blots (exosome markers: CD9, TSG101, HSP70). Dotted
arrows represent one-time validation techniques by gel-filtration and western blots of collected
supernatant and re-dissolved exoCAT-SKL from ultracentrifugation. Confirmed loading and
purification of exoCat-SKL precede intranasal injection.
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2.3 ExoCAT-SKL verification
Following exoCAT-SKL loading and purification, western blot techniques were
implemented to identify fractions containing exoCAT-SKL or CAT-SKL as well as verify
ultracentrifuge methods. Protein concentrations of each fraction were determined using
bicinchoninic acid assays (Thermo Fisher Scientific, Massachusetts, USA). Exosome membrane
proteins, TSG101 and CD9, were detected using primary rabbit anti-TSG101 (1:1000; Abcam,
Massachusetts, USA) or rabbit anti-CD9 (1:500; Abcam, Massachusetts, USA) antibodies
respectively. Supplemental exosome protein markers, HSP70, were detected using anti-HSP70
(1:1000; Abcam, Massachusetts, USA). CAT-SKL protein bands were detected using rabbit anticatalase (1:1000; Abcam, Massachusetts, USA) antibodies. Membranes were incubated using
secondary horseradish peroxidase-conjugated goat anti-rabbit antibodies, and protein bands were
detected using chemiluminescence substrate and visualized on a ChemiDoc Imaging System
(BioRad, Philadelphia, USA).
Catalase activity of prepared exoCAT-SKL was determined by hydrogen peroxide (H2O2)
decomposition assays (Storrie and Madden, 1990; Koepke et al., 2008; Walton and Pizzitelli,
2012). Protein concentrations of each fraction were determined using bicinchoninic acid assays
(Thermo Fisher Scientific, Massachusetts, USA). Samples of each fraction collected from the gelfiltration column were added to a reaction mixture of 0.02 M imidazole buffer (pH 7.0), 1 mg/mL
bovine serum albumin (BSA), 0.2% Triton-X, and 0.06% hydrogen peroxide and incubated at
room temperature for 10 minutes. The reaction was completed using a titanium oxysulfate stop
solution (TiOSO4 in 2N H2SO4), which reacts with the remaining hydrogen peroxide not
decomposed by the CAT-SKL to produce a yellow peroxotitanium complex. Optical density (OD)
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of each sample was measured at 405 nm, and catalase activity was calculated based on the
difference in OD per minute per mg total protein.

2.4 Animal Handling and Care
All animal handling and experimental procedures were approved by Western University
Animal Care Committee (AUP 2018-068) and carried out in accordance with the guidelines of the
Canadian Council on Animal Care and National Institute of Health Guides for the Care and Use
of Laboratory Animals. For Aim 1, 29 wildtype (C57BL6) mice (17 males, 12 females) between
the ages of eight and 16 weeks were involved in the study. For Aim 2, a total of 19 animals, nine
3xTG-AD mice and ten control (B6129SF2/J), were used in the study. All mice were housed under
standard conditions (12:12 light/dark cycle, at 22-24°C) and maintained on a standard diet
provided ad libitum.

2.5 Aim 1 – Timeline
The timeline for aim 1 of the study is shown in figure 2.
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Figure 2. Aim 1 timeline. Biotinylated CAT-SKL was loaded into exosomes via six cycles of
sonication for 4 seconds and 2 seconds in-between. The loaded exosomes (exoCAT- SKL) were
subsequently purified from unbound CAT-SKL using either gel filtration or ultracentrifugation.
Loading of exosomes was verified via BCA and H2O2 decomposition assays and Western Blots
(exosome markers: CD9, TSG101, HSP70). Male and female 8-week old C56BL/6 wildtype mice
received intranasal administrations of empty exosomes, low dose exoCAT- SKL (30 μL), or high
dose exoCAT-SKL (60 μL), once per week for four consecutive weeks. Mice were subsequently
sacrificed and processed for tissue collection. Pathological and histological assessments were
performed on the brain as well as off-target tissue.

2.6 Aim 1 – Treatment groups and dosing regimen
Animal numbers for each experimental group were as follows: male empty exosomes, n=
7; male low exoCAT-SKL, n=5; male high exoCAT-SKL, n= 5; female empty exosomes, n= 2;
female low exoCAT-SKL, n=5; female high exoCAT-SKL, n=5. Mice assigned to high exoCATSKL groups were subjected to 3 intranasal administrations of 10 μL per nostril of prepared
exoCAT-SKL while mice assigned to low exoCAT-SKL groups were subjected to 3 sequential
intranasal administration of 5 uL per nostril. All intranasal administrations were performed by
holding mice in a supine position and held there for 2 minutes following each administration. Mice
assigned to the empty exosome group were subjected to 3 intranasal administration of 5 uL of
exosomes per nostril. All mice received intranasal administration of empty exosomes, low or high
dose exoCAT-SKL once per week for four consecutive weeks.
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The dosing regimen to test the safety of intranasal exoCAT-SKL injection in this study is
based upon previous work by Nell et al. in which rats were treated with intraperitoneal CAT-SKL
injections once per week for four sequential weeks at 1 mg/kg (Nell et al., 2017). A similar
injection paradigm was explored by Giordano et al. in which C57Bl/6 mice were subcutaneously
injected once a week with CAT-SKL for 3 to 4 months at 1 mg/kg (Giordano et al., 2015). In this
study, multiple doses, in addition to empty exosomes, were used to determine any potential dosedependent responses.

2.7 Aim 2 – Pilot study timeline
The timeline for aim 2 of the study is shown in figure 3.

Figure 3. Aim 2 pilot study overview. CAT-SKL was loaded into exosomes via six cycles of
sonication for 4 seconds and 2 seconds in-between. Loaded exosomes were subsequently purified
from unbound CAT-SKL using ultracentrifugation. Loading of exosomes was verified via BCA
and H2O2 decomposition assays and Western Blots (exosome marker: CD9). Batches of CATSKL loaded exosomes (exoCAT-SKL) were stored at -80oC for up to 5 weeks for subsequent
injections. Male and female 8-week old B6129SF2/J control mice, 3xTG-AD mice, received
intranasal administrations of empty exosomes, or 60 uL of exoCAT-SKL once per week for 24
consecutive weeks. Immediately following the last injection, the Morris water maze task was
implemented to evaluate mouse behaviour, learning deficits, memory and cognitive impairments.
Mice were sacrificed and perfused following behavioural testing; the brains and off-target tissue
were collected and processed. Pathological and histological assessments were performed on all
tissue.

2.8 Aim 2 – Treatment groups and numbers
The treatment groups and numbers for aim 2 of the study is shown in figure 4.
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1

Figure 4. Aim 2 cohort 1 treatment groups and numbers. A total of 10 B6129SF2/J control
mice and nine 3xTG-AD mice make up cohort 1 of Aim 2. Of the control mice, listed following
are the treatment groups: males receiving empty exosomes, females receiving empty exosomes,
males receiving high dose exoCAT-SKL, females receiving high dose exoCAT-SKL. Of the 3xTG
mice, listed following are the treatment groups: males receiving empty exosomes, females
receiving empty exosomes, males receiving high dose exoCAT-SKL, females receiving high dose
exoCAT-SKL.

2.9 Euthanasia and Tissue Collection
Following the final injection (week 4), mice were euthanized using a CO2 chamber and
weighed. Transcardial perfusion using 0.01 M PBS (pH 7.35), followed by 4% paraformaldehyde
(pH 7.35), was performed for all mice. Brains were subsequently extracted, weighed, and
submerged in paraformaldehyde for 24 hours and then transferred to a 30% sucrose solution until
brains were saturated and fully submerged. Brains were sectioned coronally on a cryostat at 30 μm
thickness approximately from bregma 3.75 mm to bregma -7.50 mm, sorted into series and stored
in cryoprotectant at -20°C until used for histological and immunofluorescent techniques. All other
organs were harvested, weighed, trimmed, and stored within cassettes and embedded in paraffin
wax. As per the Society of Toxicologic Pathology, a list of all organs collected for histopathologic
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examinations is listed in Table 1 (Bregman et al., 2003).

Table 1: List of tissues included for histological examination
Organ Systems

Organs

Secretory Glands

Adrenal, Harderian, Kidney, Mammary, Parathyroid,
Pituitary, Pancreas, Salivary, Thymus, Thyroid

Muscular Skeletal

Femur with articular cartilage, Bone marrow, Skeletal
muscle (thigh), Skin

Reproductive

Epididymis, Seminal Vesicle, Testes, Ovary, Prostate,
Uterus, Vagina

Central and Peripheral Nervous

Brain, Eye with optic nerve, Peripheral nerve (sciatic),
Spinal cord (cervical, midthoracic, lumbar)

Gastrointestinal Tract

Cecum, Colon, Duodenum, Esophagus, Gall Bladder,
Ileum, Jejunum, Liver, Stomach, and Urinary Bladder

2.10 Histology
Organs and brain sections were mounted onto slides and stained with 0.1% Mayer’s
hematoxylin solution and 0.5% eosin Y solution, dehydrated, and coverslipped at the Robarts
Research Institute Molecular Pathology Core Facility. Free-floating brain sections were prewashed in 0.01 M PBS, mounted on glass slides, and dried overnight.

2.11 Immunofluorescence
Immunofluorescence was performed on free-floating sections to visualize bCAT-SKL in
the brain. Following PBS washes, sections were blocked in 1% BSA diluted in 0.01 M PBS/0.1%
Triton X and subsequently incubated in Streptavidin Texas Red Conjugate (1:250, Abcam,
Massachusetts, USA) for 2 hours diluted in antibody buffer. Sections were mounted on glass slides,
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and DAPI fluorescent mounting medium (Abcam, Massachusetts, USA) was applied, and slides
were subsequently coverslipped.

2.12 Immunohistochemistry
Immunohistochemistry was performed on free-floating sections to visualize microglia in
the brain. Following PBS washes, sections were blocked in 1% horse serum diluted in 0.01 M
PBS/0.1% Triton X and subsequently incubated overnight at 4ºC in primary rabbit polyclonal
antibody against the ionized calcium-binding adaptor molecule-1 (anti-Iba-1; 1:1000; Wako
Chemicals USA Inc., Richmond, VA, USA). Sections were subsequently incubated with
biotinylated anti-rabbit secondary antibody (1:500, Vector Laboratories, Inc. Burlingame, CA,
USA) followed by a 1-hour incubation with avidin-biotin complex (ABC kit, Vector Laboratories,
Inc. Burlingame, CA, USA) reagent. Sections were developed using 0.05% 3, 3’ diaminobenzidine
tetrahydrochloride (Sigma-Aldrich, St. Louis MO, USA). Stained sections were then mounted on
glass slides, air-dried, dehydrated in increasing concentrations of ethanol and xylene, and
coverslipped with DePex mounting media (DePex, BDH Chemicals, Poole, UK).

2.13 Microscopy
Immunofluorescent, immunohistochemical, and histological imaging of organs and brain
sections were taken using Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2 black and
white camera head or colour camera. Images were taken using the NIS-Elements Imaging Software
Version 4.30.02 (Nikon Instruments Inc., Melville, NY, USA) with consistent settings. Brain
regions of interest included the prefrontal cortex, striatum, dorsal and ventral hippocampus, and
the cerebellum.
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2.14 Immunohistochemistry Quantification
Entire brain sections stained for IBA1 positive cells were imaged at 2X to quantify changes
in general microglia populations. Sections of bregma 1.7 mm to bregma 1.8 mm were screened
for positive IBA1 signal to determine regions of interest. All analysis and quantification were
carried out using 64-bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA). Areas of interest included the hippocampus and the corpus callosum
and were manually outlined using the polygon selection tool. Selected areas were cropped and
converted into grayscale 8-bit images and underwent universal thresholding. The percent area of
positive IBA1 signal (percent of the total area) was measured for each region and expressed as a
weighted mean.

2.15 Behaviour: Morris Water Maze
To assess brain areas associated with AD, cognitive testing using preclinical animal models
has proven useful. Hippocampal dependent spatial learning and memory can be assessed in
rodents using the Morris water maze (MWM) task, first developed by Richard Morris in the early
1980s (Morris, 1984). Tools such as the Morris water allows for the investigation of behavioural
deficits caused by vulnerable brain areas as well as the impact of novel drugs. The MWM protocol
published by Frame et al. 2019 was used in this study and explained as followed (Frame et al.,
2019).

MWM equipment and layout:
The objective of the task is for each mouse to learn the location of an escape platform in a
circular polyurethane water tank, 122 cm in diameter, 81 cm height (San Diego Instruments,
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catalogue number: 7000-0723, USA) using distal spatial cues. An escape platform made of clear
acrylic, 10 cm diameter, 56 cm height (San Diego Instruments, catalogue number: 7500-0310,
USA) was hidden in the pool using an opaque water mixture of non-toxic white tempera paint
(0.34 g/L). The pool was filled within 20 cm to the top such that the escape platform was
submerged ~1 cm below the surface. The water temperature was maintained at 24 ± 1°C
throughout all testing days. Different spatial cues (distinct in colour and shape; blue triangle,
yellow cross, red heart, green circle, grey diamond) were placed around the tank on the north, east,
south and west walls of the testing area with transparent tape 1-2 m away from the pool. A camera
was placed on the ceiling directly above the tank, allowing for complete capture of the entire tank
in the same plane. Using ANY-Maze software (ANY-maze, Stoelting CO, USA), a virtual map of
the MWM tank was drawn. The pool was virtually divided into four equal quadrants using
horizontal and vertical lines that cut through the center point. Quadrants were labelled North-east,
North-west, South-west, and South-east. The submerged exit platform area was also virtually
marked using the ANY-maze software. All mice completed an 8-day protocol – 3 days of
habituation, four days of learning, and a probe trial for 24 h long-term memory on the final day.

Habituation period:
All mice underwent three days of habituation. Mice were acclimatized to the holding area
for 30 minutes on day 1 and returned to the normal housing room. On day 2, each mouse was
placed on the exit platform positioned in the center of the maze. Immediately after placing the
mouse on the platform, the mouse was given 15 uninterrupted seconds to acclimate to the exit
platform and extra-maze visual cues. On day 3, mice were acclimatized to the training procedure.
The exit platform remained in the center of the maze in the testing area. The trial began when a
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mouse was placed in the water on the perimeter of the maze at a randomly chosen cardinal position
(south) facing the wall of the pool. Each mouse was given 90 seconds to find the exit platform.
Once the mouse found the platform, the mouse was again given 15 seconds before removing it
from the testing area.

Learning period:
Over four days, four training sessions were implemented to induce spatial learning
following the acclimation period. The exit platform was moved from the center of the pool to the
center of the Northwest quadrant for the duration of all learning trials. The objective of these trials
was to have the mice recognize the extra-maze visual cues to help establish the spatial location of
the hidden exit platform. On the first day, each mouse performed 4 trials with a 10-minute intertrial time interval starting at the same cardinal position (south) used during the habituation session
and facing the pool wall. Mice were given 90 seconds to search and locate the exit platform. An
additional 15 seconds was given to the mouse to sit on the platform and absorb the surroundings.
If the mouse had not found the platform in the allocated time, the mouse was gently guided to the
platform and ensured 15 seconds on the platform before being removed from the pool. For each
subsequent trial, mice were released in the cardinal direction that was one quarter turn clockwise
(east, north, then west) from the previous trial. The initial starting position for each subsequent
day was one quarter turn clockwise from the starting position of the previous day. Using the ANYmaze software, each mouse's latency and distance to the exit platform, and mean swim speed was
recorded.
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Probe trial:
A probe trial (exit platform was removed from the pool) was conducted to assess 24-hour
long-term memory following the last learning trial. The probe trial began with each mouse being
placed at the same cardinal direction (north) used during the habituation period. Mice were allowed
60 seconds to explore the maze. As recorded using ANY-maze software, the amount of time spent,
and the distance travelled in the target quadrant (Northwest - where the exit platform had been
during the learning period) is taken as an index of the mouse's learning and 24-hour memory
capacity. Mean swim speed and latency to where the exit platform had previously been was also
analyzed.

Flag Trial:
Immediately following the probe trial, a flag trial was implemented to test the visuospatial
navigation of each mouse. This test was used to control for potential differences in the MWM task
between mice attributed to motivation or visual acuity. Extra-maze visual cues were removed from
the testing area, and the exit platform was returned to the pool and placed in the center of the
southeast quadrant diametrically opposite the original position (northwest) of the learning period.
A flag was attached to the platform above the surface of the water, marking its location. Each
mouse was allowed to acclimate to the new set of conditions and placed on the platform for 30
seconds. Immediately after, each mouse was given a second trial and placed back in the pool at
the same cardinal position (south) as the habituation period facing the wall. Due to the removal of
extra-maze visual cues, the platform's location can only be discovered due to the flag's presence.
The latency and distance travelled to the platform, as well as mean swim speed was recorded using
ANY-maze software.
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2.16 Data and Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0. Collected data were analyzed
by either a three-way or two-way analysis of variance (ANOVA), followed by a Fisher’s LSD test
where applicable. All data are expressed as the mean ± the standard error of the mean (SEM) with
statistical significance considered at a p-value < 0.05. Statistical significance is indicated using
symbols * and ‡.
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Section 3: RESULTS
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3.1 Aim 1 Results:

3.1.1 bCAT-SKL loaded exosomes can be purified using gel filtration and maintain enzymatic
activity.
Short burst sonication was implemented to load bCAT-SKL into naïve exosomes derived
from Raw 264.7 macrophages by disrupting the exosome membrane allowing for bCAT-SKL
incorporation. Sonication was used due to its high loading efficacy compared to other protein
incorporation techniques such as saponin permeabilization, freeze-thaw cycles, or extrusion
(Haney et al., 2015). Unbound bCAT-SKL was removed using gel filtration chromatography with
a Sepharose 6BCL column as described in the methods. Protein concentrations of collected
fractions were measured using a BCA assay to confirm the separation of packaged and unpackaged
bCAT-SKL (Figure 5A). Results of the representative assay demonstrated that fractions 6 and 7
contained relatively higher protein concentrations. The first peak (fractions 6 and 7) corresponds
to both exosome proteins as well as packaged bCAT-SKL. The second protein peak (fractions 914) corresponded to the unbound bCAT-SKL. This double peak pattern was mirrored in bCATSKL enzymatic activity, as indicated in a representative H2O2 decomposition assay of collected
fractions (Figure 5B). Early fractions 6 and 7 correspond to the catalase activity of exosome
packaged bCAT-SKL, while later fractions 9-14 showcase the catalase activity of unbound bCATSKL. Western blot techniques were used to confirm the presence of both exosome proteins and
bCAT-SKL in early fractions and bCAT-SKL alone in later fractions (Figure 5C). Supplemental
exosome markers CD9 and HSP70 were also utilized to confirm the presence of loaded exosomes
(Figure 2D). The separation function of gel-filtration chromatography is dependent on molecular
size. Larger molecules are filtered through the column at a faster rate than smaller molecules.
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bCAT-SKL (a smaller molecule than exosomes) can only be collected into earlier fractions if
incorporated into exosomes. The combination of all three techniques demonstrated the successful
loading and purification of exoCAT-SKL without disrupting its enzymatic activity.

Figure 5. Loaded exoCAT-SKL can be purified using gel-filtration chromatography.
A) Representative BCA assay of collected fractions following gel filtration. The protein peak
corresponding to exosome packaged bCAT-SKL occurred in early fractions (6-7; red) while the
unbound catalase protein peak occurred in later fractions (10-14; blue). B) Representative H2O2
decomposition assay of collected fractions following gel filtration. The H2O2 decomposition
activity peak corresponding to exosome packaged bCAT-SKL occurred in early fractions (6-7;
red) while the unbound catalase activity peak occurred in late fractions (9-16; blue). Fractions 916 displayed catalase activity outside the linear range of the H2O2 decomposition assay. C)
Representative western blot confirmed the presence of catalase and exosomes in fraction 6.
Unbound catalase was found in later fractions 11-14. D) Supplemental exosome markers CD9 (24
kDa) and HSP70 (70 kDa) were used to confirm the presence of loaded exosomes in gel filtration
fractions.
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3.1.2 Ultracentrifuge purification of ExoCAT-SKL and stability of enzymatic activity following
freeze-thaw cycle
Ultracentrifuge purification was used as an alternative method to produce exoCAT-SKL.
Stronger centrifugal forces were required to pellet CAT-SKL compared to exoCAT-SKL due to
their difference in molecular weight. An MLA13-rotor spun at 50 k RPM, as used in this study,
translated to 100,000 x g force and had been shown to pellet exosomes (Szatanek et al., 2015).
Western blot techniques were implemented to confirm the successful purification of exoCAT-SKL
using ultracentrifuge methods (Figure 6A). Exosome membrane protein, CD9, and CAT-SKL
proteins were found within the resuspended pellet, and only CAT-SKL protein was found in the
first supernatant. Trace levels of CAT-SKL protein were found in the second supernatant,
confirming the successful removal of unbound CAT-SKL. The catalytic activity of purified
exoCAT-SKL before and after one freeze-thaw cycle was confirmed using H2O2 decomposition
assays (Figure 6C). Thawed exoCAT-SKL was also filtered through a gel-filtration column, and
western blot assays of collected fractions confirmed the presence of CAT-SKL within exosomes
(Figure 6D). Results of the western blot and H2O2 decomposition assays confirm successful
exoCAT-SKL ultracentrifuge purification and retainment of enzymatic activity following one
freeze-thaw cycle.
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Figure 6. Loaded exoCAT-SKL can be purified using ultracentrifuge techniques, and thawed
exoCAT-SKL retains enzymatic activity. A) Representative western blot confirmed the presence
of both CAT-SKL and exosomes in the resuspended exoCAT-SKL pellet (labelled EXO CAT).
Only CAT-SKL was found in the first supernatant and trace levels in the second supernatant. B)
Representative H2O2 decomposition assay showcased strong exoCAT-SKL enzymatic activity
before freezing. A 1:50 dilution of the resuspended exoCAT-SKL equated to 9 ng/µL CAT-SKL
C) Representative western blot confirmed the presence of CAT-SKL and exosomes in early
fractions (fractions 5-7) collected from gel-filtration assay following one freeze-thaw cycle. D)
Representative H2O2 decomposition assay showcased thawed exoCAT-SKL retained strong
enzymatic activity.
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3.1.3 Intranasal administration of exoCAT-SKL demonstrates the ability to penetrate the BBB in
vivo.
Immunofluorescent and confocal imaging techniques were implemented to visualize
bCAT-SKL deposition in WT mice brains. Mice were intranasally administered empty exosomes,
low, or high doses of exoCAT-SKL (Figure 7). bCAT-SKL was immunofluorescently labelled to
identify its biodistribution 1 hour following the final administration. The imaging revealed diffuse
bCAT-SKL positive signal throughout the brain (bregma 0.5 to bregma -2.75) including areas of
interest such as the prefrontal cortex, corpus callosum, and the hippocampus. Higher magnification
of brain sections showed bCAT-SKL localization in the perinuclear region (Figure 7 - yellow
arrow) and the vessel walls (Figure 7 - white arrow). Images of the control brain injected with
empty exosomes demonstrated a complete absence of bCAT-SKL fluorescent signal (Figure 7 Control 40X). Fluorescent imaging of bCAT-SKL demonstrated that intranasal administration of
exoCAT-SKL is an effective delivery mechanism to penetrate the BBB and target the CNS of
mice.
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Figure 7. Intranasal administration of exoCAT-SKL penetrated BBB in vivo. Pervasive
biodistribution of biotinylated CAT-SKL (red) following low and high dose intranasal exoCATSKL injection was observed throughout the brain. 40X magnification and 40X-Digital
Enhancement (DE; 40X area resize) of the prefrontal cortex, corpus callosum and hippocampus
are showcased. The white arrow in the figure showcases the vasculature deposition of bCAT-SKL.
Yellow arrow showcases cellular deposition of bCAT-SKL.
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3.1.4 Short-term in vivo exoCAT-SKL administration does not exhibit toxicity in the brain
Histopathological analysis of H&E stained brain tissue determined whether degenerative
or toxic changes occurred in mice following four weeks of exoCAT-SKL treatment compared to
control mice (Figure 8). Serial sections throughout the brain (bregma 2.8 mm to bregma -6.6 mm),
including anatomical structures encompassing predicted exoCAT-SKL absorption pathways such
as the piriform cortex, were analyzed to account for widespread bCAT-SKL biodistribution.
Representative images of the prefrontal cortex, corpus callosum, hippocampus, and cerebellum are
showcased. Neuronal injury within the grey matter was not observed under microscopic
examination in any of the treatment groups evidenced by the absence of eosinophilia of the
cytoplasm, shrinkage or disappearance of the nucleolus, disintegration of the cell, amongst other
characteristics of injury. Neuronal atrophy or neuronal necrosis was not observed in any treatment
group. Reactive inflammation was not observed, and a normal distribution of neural cells was
observed in all treatment groups. No vasculature abnormalities nor lesions were identified
throughout the tissue and white matter tracks did not contain degenerative changes (i.e.
vacuolation, spheroids). No evidence of toxicity was identified throughout the brain for all
treatments and doses.
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Figure 8. ExoCat-SKL does not cause toxicity in the brain in vivo. The prefrontal cortex
(bregma 2.8 mm), corpus callosum (bregma 0.5 mm), hippocampus (bregma -1.8 mm), and
cerebellum (bregma -6.6 mm) sections were selected to represent the entirety of the brain. All
sections were examined for features of toxicity, including but not limited to spongiosis, neuron
degeneration, inflammation, and vasculature abnormalities. Representative 10X magnification of
boxed areas is showcased. All features of toxicity are negative in all areas of mice treated at
different doses of exoCAT-SKL.
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3.1.5 Short term in vivo intranasal exoCAT-SKL administration does not exhibit off-target toxicity.
In addition to assessing the toxicity of exoCAT-SKL in the brain, off-target toxicity was
assessed to validate the utility of this therapeutic approach. The Society for Toxicologic
Pathology's (STP) best practices guideline for toxicologic histopathology was utilized to ensure
high-quality histologic assessments. No significant differences were observed in relative organ
weight of the brain, liver, spleen, nor in the thymus, heart, kidney, adrenal glands, testis and ovaries
compared between treatment groups. All features of toxicity were negative in off-target
tissue (Table 2).

Table 2: Features of toxicity of tissues included for histological examination
Organ Systems
Secretory Glands
Muscular Skeletal
Reproductive
Central and
Peripheral Nervous
Digestive

Organs
Adrenal, Harderian, Kidney, Mammary, Parathyroid,
Pituitary, Pancreas, Salivary, Thymus, Thyroid
Femur with articular cartilage, Bone marrow, Skeletal
muscle (thigh), Skin
Epididymis, Seminal Vesicle, Testes, Ovary, Prostate,
Uterus, Vagina
Eye with optic nerve, Peripheral nerve (sciatic), Spinal
cord (cervical, midthoracic, lumbar)
Cecum, Colon, Duodenum, Esophagus, Gall Bladder,
Ileum, Jejunum, Liver, Stomach, and Urinary Bladder
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Toxicity
Negative
Negative
Negative
Negative
Negative

3.2 Aim 2 pilot study results
3.2.1 Behaviour testing: Morris water maze
The Morris water maze task was implemented to examine if 24 weeks of intranasal
exoCAT-SKL injections improved memory or learning deficits in control and 3xTG AD mice. All
mice underwent four days of learning, followed by a probe trial on the 5th day to assess 24-hour
long-term memory. The amount of time spent, and the distance travelled in the target quadrant
(area of the maze where the exit platform had been during the learning period) during the probe
trial was taken as an index of each mouse’s learning and 24-hour memory capacity.

Latency to platform and swim speed during the learning period
Following the last exoCAT-SKL injection, all mice were subjected to a 4-day training
regimen with four trials each day for a total of 16 spatial learning trials. No significant interactions
between time, genotype, and treatment were observed for both latency to platform by trial and by
day. A significant time-dependent effect was observed for the latency to platform by trial (F15,240
= 4.154, P < 0.001) (Figure 9A), and for the latency to platform by day (F3,60 = 5.816, P < 0.01)
(Figure 9B). No significant interactions between variables were observed in measured swim
speeds. Significant genotype dependent differences in swim speed were observed between groups
(Figure 9C). The control empty exosome group swam significantly slower than the 3xTG AD
empty group across the days.
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Figure 9. Morris water maze learning trials following 24 weeks of intranasal injections of
either empty exosomes or high dose exoCAT-SKL. A) The mean latency to the exit platform
for each treatment group per trial is plotted. Vertical dotted lines indicate the first trial of the
following day (i.e. trial 5 is 24 hours following trial 4). Mice that did not reach the platform during
the trial were recorded as 90 seconds (time indicating the trial endpoint). No significant
interactions between time, genotype, and treatment were observed for the latency to platform by
trial. A significant time-dependent effect was observed (F15,240 = 4.154, P < 0.001). B) The mean
latency to the exit platform area of each treatment group per day is plotted. No significant
interactions between time, genotype, and treatment were observed for the latency to platform by
day. A significant time-dependent effect was observed (F3,60 = 5.816, P < 0.01). C) The mean swim
speeds of each treatment group were compared per day during the learning trials. No significant
interactions between variables were observed in measured swim speeds. Significant genotype
dependent differences in swim speed were observed between groups The Control Empty group
swam slower than both 3xTG groups on day 1, day 2, and day 3. Significant differences were
observed between Control High Dose ExoCAT-SKL group compared to both 3xTG groups on day
3 and day 4. Values are presented as mean ± SEM (Three - way ANOVA).
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Distance to the exit platform during the learning period
The distance to the exit platform during the learning period accounts was analyzed to
account for variability in swim speeds between treatment groups. No significant interactions
between time, genotype, and treatment were observed for both distance to platform by trial and by
day. Significant time-dependent (F15,240 = 3.340, P < 0.0001), genotype-dependent (F1,240 = 23.81,
P < 0.0001), and treatment-dependent sources of variation (F1,240 = 5.503, P < 0.05) were observed
in the distance to platform by trial (Figure 10A). In addition, significant time-dependent (F3,60 =
5.639, P < 0.01), genotype-dependent (F1,60 = 19.85, P < 0.0001), and treatment-dependent sources
of variation (F1,60 = 4.589, P < 0.05) were observed in the distance to platform by day. The same
pattern was seen in the latency to the exit platform during the learning period.
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Figure 10. Morris water maze learning trials following 24 weeks of intranasal injections of
either empty exosomes or high dose exoCAT-SKL. A) The mean distance to the exit platform
area of each group per trial is plotted. The distance to the platform reflects path efficiency. Vertical
dotted lines indicate the first trial of the following day (i.e. trial 5 is 24 hours following trial 4).
Mice that did not reach the platform during the trial were recorded with the total distance swam
reflecting the trial endpoint. No significant interactions between time, genotype, and treatment
were observed for the distance to platform by trial. Significant time-dependent (F15,240 = 3.340, P
< 0.0001), genotype-dependent (F1,240 = 23.81, P < 0.0001), and treatment-dependent sources of
variation (F1,240 = 5.503, P < 0.05) were observed in the distance to platform by trial. The distance
to the platform was significantly shorter over the course of the trials for all treatment groups except
for 3xTG AD mice treated with high dose exoCAT-SKL. B) The mean distance to the platform of
each group per day is plotted. No significant interactions between time, genotype, and treatment
were observed for the distance to platform by day. Significant time-dependent (F3,60 = 5.639, P <
0.01), genotype-dependent (F1,60 = 19.85, P < 0.0001), and treatment-dependent sources of
variation (F1,60 = 4.589, P < 0.05) were observed. Values are presented as mean ± SEM (Three way ANOVA).
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Probe trial: 24-hour long-term memory retention does not demonstrate significant differences
Twenty-four hours following the last learning trial, mice were subjected to a probe trial.
Several measurements were recorded as an index of each mouse's memory capacity: the percentage
of time spent in the target quadrant (Figure 12A), the number of removed platform area entries
(Figure 12 B), latency to removed platform area (Figure 12C) and distance to removed platform
area (Figure 12D). No significant differences were observed in any of the interactions and
measurements between all treatment groups.
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Figure 11. Indications of short-term memory during the probe trial. A) The time spent in the
target quadrant is expressed as a percent of the total time of the probe trial. The horizontal dotted
line represents the theoretical amount of time spent in the target quadrant due to chance. No
significant differences amongst groups were observed. B) The number of removed platform area
entries per group are indicated. No significant differences were observed. C) The mean latency to
the removed platform area of each group is plotted. Mice that did not reach the area during the trial
were recorded as 60 seconds (time indicating the trial endpoint). No significant differences were
observed. D) The mean distance to the removed platform area of each group is plotted. Mice that
did not reach the area during the trial were recorded with their total swim distance during the entire
trial. No significant differences were observed. Values are presented as mean ± SEM (Two–way
ANOVA).
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Flag Trial:
On the final day immediately following the probe trial, a single flag trial was conducted as
a control procedure to examine if any differences observed in the MWM task was attributed to
extraneous factors such as visual impairment and lack of motivation. All mice were acclimated to
a flag placed upon the platform indicating its position in the MWM. The latency to the flagged
platform was recorded (Figure 12). No significant differences between genotypes, treatments, and
interactions were observed demonstrating that all mice had similar motivation and abilities to find
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Figure 12. Latency to the platform during flag trial. The mean latency to the platform of each
group is plotted. All mice reached the platform within the allocated trial time. No significant
differences were observed between groups. Values are presented as mean ± SEM (Two – way
ANOVA).
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3.2.2 Anatomical changes
Mice were weighed once a week on the day of the exoCAT-SKL intranasal administration
for 24 weeks. The change in body weight was calculated as the mouse's weight on the day of
sacrifice (Figure 13A) subtracted by the weight of the mouse on the first intranasal injection. No
significant sources of variation were observed in the interactions between genotype and treatment
for all measurements. No significant body weight changes were identified between all treatment
groups (Figure 13C). Post-mortem brain weights were also recorded on the day of sacrifice (Figure
13B). The relative brain to body weight was calculated as the ratio of the brain weight to the mouse.
No significant differences were observed in normalized brain weights amongst all treatment
groups (Figure 13D).
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Figure 13. Weight gain, brain weight, and relative brain weight. A) The mean weight of each
treatment group at time of sacrifice. B) Means of raw brain weight at the time of sacrifice of each
treatment group is plotted. C) The mean change in body weight over 24 weeks of injections was
tracked for all treatment groups. No significant differences were observed. D) The relative brain
to body weight is expressed as a percentage of total body weight. No significant differences were
observed between all treatment groups. Values are presented as mean ± SEM (Two - way ANOVA).
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3.2.3 Long-term exoCAT-SKL administration does not exhibit toxicity in the brain in vivo.
Histopathological analysis of H&E stained brain tissue determined whether degenerative
or toxic changes occurred in mice that underwent 24 weeks of intranasal exoCAT-SKL treatment.
Mimicking Aim 1, serial sections throughout the brain, were analyzed to account for widespread
bCAT-SKL biodistribution. Representative images of bregma 2.5 mm to bregma -6.2 mm are
shown (Figure 14).
Neuronal injury within the piriform cortex, cerebral cortex, anterior and posterior corpus
callosum, dorsal and ventral hippocampus, and the cerebellum was not observed under
microscopic examination in any of the treatment groups. Features of toxicity examined included
the absence of eosinophilia of the cytoplasm, shrinkage or disappearance of the nucleolus,
disintegration of the cell, amongst other characteristics of injury. In addition, neuronal atrophy or
neuronal necrosis was not observed in any treatment group. Reactive inflammation could not be
accurately reported using H&E analysis; however, a normal distribution of neural cells was
observed in all treatment groups. No vasculature abnormalities nor lesions were identified
throughout the tissue and white matter tracks did not contain degenerative changes (i.e.
vacuolation, spheroids). No evidence of toxicity was identified throughout the brain for both
genotypes and treatments.
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Figure 14. Chronic exoCAT-SKL injections do not cause toxicity in the mouse brain in vivo.
Representative sections of bregma 2.5 mm to bregma -6.2mm are selected to portray the entirety
of the brain. All sections are stained with hematoxylin and eosin for features of toxicity, including
but not limited to spongiosis, neuron degeneration, inflammation, and vasculature abnormalities.
Representative 10X magnification of boxed areas of all treatment groups is showcased. All
features of toxicity are negative in all areas for control and 3xTG AD mice treated with empty
exosomes and high doses of exoCAT-SKL.
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3.2.4 Neuroinflammation: Microglia reactivity
Immunohistochemical analysis of IBA1 stained brain tissue of mice intranasally injected
with exoCAT-SKL for 24 weeks was performed to investigate microgliosis. Pathology in the
corpus callosum and hippocampus were of particular interest due to their association with memory
and cognitive function. Representative images of the of bregma 1.7 mm to bregma -1.8 mm are
shown (Figure 15A). No significant differences were observed in the interactions between
genotype and treatment. A significant genotype-dependent increase in Iba-1 positive microglia in
the hippocampus (F1,32 = 34.57, P < 0.0001) and the corpus callosum (F1,15 = 8.984, P < 0.01) was
observed. Both 3xTG AD groups had significantly more percent IBA1 microglia coverage in the
hippocampus and corpus callosum than their control counterparts (Figure 15B,C).
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Figure 15. Total microglia in the brain. A) Representative images of Iba-1 immunolabelled
microglial cells throughout brain sections of bregma 1.7 mm to bregma 1.8 mm are showcased.
2X digitally enhanced magnification of boxed areas of the left column is shown for all treatment
groups. 2x digitally enhanced insets of areas of interest included the piriform cortex, corpus
callosum, medial septal nucleus, and hippocampus. B) Percent area of IBA1 positive microglia in
the hippocampus is shown. No significant differences were observed in the interactions between
genotype and treatment. A significant genotype effect was observed (F1,32 = 34.57, P < 0.0001). C)
Percent area of IBA1 positive microglia in the corpus callosum is shown. No significant
differences were observed in the interactions between genotype and treatment. A significant
genotype dependent effect was observed (F1,15 = 8.984, P < 0.01). Values are presented as mean ±
SEM (Two - way ANOVA).
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Section 4: DISCUSSION
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The results of this study provided the foundation for using macrophage-derived exosomes
to deliver the recombinant antioxidant, CAT-SKL, to the brain. This approach could act as a
potential therapeutic strategy for many neurodegenerative disorders by addressing two
complementary issues: i) an important antioxidant cargo, and ii) a therapeutically promising
delivery method.
The function of CAT-SKL in metabolizing H O into less toxic derivatives and its ability
2

2

to target peroxisomes directly holds tremendous promise for managing cellular ROS. CAT-SKL
was previously shown to protect neurons, reduce cell death and neuroinflammatory responses
elicited in cell culture models of neurodegeneration (Giordano et al., 2014). In addition, studies
have shown intraperitoneal injections of CAT–SKL reduced neuroinflammation and memory
deficits in a rat model of AD (Nell et al., 2017). Although CAT-SKL had been demonstrated to be
protective in numerous preclinical models, these previous studies were limited by biodistribution,
systemic degradation, and, most importantly, the inability to penetrate the BBB.
4.1 Exosomes as therapeutic drug carriers
Results from the current study (Figure 1 and Figure 2) demonstrated that sonication
techniques could be used to incorporate CAT-SKL into exosomes successfully. The hydrophilic
core of exosomes is a suitable environment for water-soluble compounds such as CAT-SKL (Jiang
and Gao, 2017). This approach allowed CAT-SKL to be protected from degradation in vivo while
maintaining H O decomposition abilities (Figure 1 and Figure 2). Similar sonication techniques
2

2

have been implemented to load exosomes successfully in other studies. Kim et al. reported that
exosomes sonicated with chemotherapy medication, paclitaxel, did not disrupt the structure and
content of exosome membranes and maintained stability in aqueous solution for over one month
(Kim et al., 2016). In addition, Haney et al. also demonstrated mild sonication of exosomes in the
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presence of endogenous catalase, provided effective loading capacity and improved its enzymatic
stability against protease degradation (Haney et al., 2015).
Gel-filtration and ultracentrifuge techniques, as used in this study, demonstrated successful
purification of exoCAT-SKL, providing promise for standardized production and purification of
loaded exosomes (Figure 1 and Figure 2A). ExoCAT-SKL enzymatic activity was not disrupted
following a freeze-thaw cycle as measured by H O decomposition assays (Figure 2D), allowing
2

2

for long term storage in future studies. This work provides further evidence that exosomes could
be a valuable tool as carriers of therapeutic proteins.
4.2 Safety of exoCAT-SKL within the brain
Although exoCAT-SKL holds tremendous potential as both an effective therapeutic and
efficient drug transport technique, the safety of its use required investigation. The use of
homologous exosomes in our study was derived from same-species monocytes, resulting in
minimal immune responses (Ha, Yang and Nadithe, 2016). Thus, an emphasis was put on the
toxicology profile of CAT-SKL in the brain and systemically in vivo. Accurate interpretation of
mouse histology provided a fundamental step in determining the feasibility of exoCAT-SKL.
Drug delivery through the intranasal route has been demonstrated as an effective and noninvasive method for targeting drug uptake into the brain (Crowe et al., 2018b). This study
demonstrated that the intranasal injection of exoCAT-SKL could successfully cross the BBB and
deposit CAT-SKL into the brain (Figure 7). No apparent abnormalities nor features of toxicity
were observed in the brains of mice treated for 4 weeks or 24 weeks of exoCAT-SKL injections
in all treatment groups. This finding provided further evidence that CAT-SKL has non-toxic
neuroprotective roles similarly described in other in vitro and in vivo studies (Giordano et al.,
2015; Nell et al., 2017). Standard catalase without the recombinant c-terminus loaded within
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exosomes have also been shown to be neuroprotective in preclinical models of Parkinson's disease
(Haney et al., 2015). The protective capacity of standard catalase in neurodegenerative models
highlights the increased potential of CAT-SKL in similar preclinical experiments.

4.3 Microgliosis
Research in AD has established that neuroinflammation contributes to the pathogenesis of
AD in addition to other hallmarks such as Aβ and neurofibrillary tangles (Raj et al., 2017). It is
well established that microglia contribute to the inflammatory response through their interactions
with Aβ and their frustrated phenotype, causing the release of pro-inflammatory cytokines,
chemokines and ROS (Xiang et al., 2006; Hemonnot et al., 2019). The IBA1 marker of microglia
was used to measure microgliosis with increased microglia reflective of neuroinflammation and
microglia activation (Imai et al., 1996; Lee et al., 2017). Results from this study demonstrated an
increased microglia response in 34-week-old 3xTG AD mice compared to their control counterpart
independent of exoCAT-SKL treatment. Consistent with these findings, previous work by Belfiore
et al. found elevated levels of IBA1 labelled microglia in the medial, caudal, and rostral
hippocampus of 3xTG AD mice at 6 months of age consistent with these findings (Belfiore et al.,
2019). The current study found no significant differences in IBA1 labelled microglia in the corpus
callosum or hippocampus between mice treated with exoCAT-SKL and mice treated with naive
exosomes of either genotype (Figure 15). These findings contradict findings by Haney et al. which
demonstrated that catalase reduced microgliosis in mice stereotaxically injected with 6hydroxydopamine, a neurotoxic compound used to destroy dopaminergic neurons (Haney et al.,
2015). In addition, Nell et al. 's findings demonstrated that intraperitoneal injections of CAT-SKL
reduced microgliosis in the medial septal nucleus and thalamus of 6-month-old rats administered
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with Aβ peptides (Nell et al., 2017). These contradictory results could be attributed to the
concentration and frequency of exoCAT-SKL injections as well as the limited numbers used in
this study. Nell et al. implemented intraperitoneal injections of CAT-SKL at 1 mg/kg once per
week while Haney et al. implemented 10 intranasal injections every other day (Haney et al., 2015;
Nell et al., 2017). The concentration of CAT-SKL that reached the brain was not quantifiable in
this study, and preliminary results did not indicate CAT-SKL elicited a detectable effect on
microgliosis

4.4 Morris water maze
The Morris water maze task was implemented to discern any learning and memory
differences induced by genotype differences or 24 weeks of exoCAT-SKL injections (Morris,
1984; Bromley-Brits, Deng and Song, 2011; Frame et al., 2019). Results from the MWM testing
were preliminary, and discrepancies between our findings to that of others can be attributed to the
lack of statistical power in Aim 2 of our study. All of the treatment groups demonstrated successful
learning of the task by swimming to the platform significantly quicker and using less distance over
the course of all trials except for the 3xTG High Dose exoCAT-SKL group (Figure 9, Figure 10).
Genotype induced differences were not observed as the 3xTG Empty group performed similarly
to Control Empty mice. This contradicts findings by Belfiore et al. that showcased 6-month-old
3xTG-AD mice developed learning deficits compared to age-matched controls (Belfiore et al.,
2019). ExoCAT-SKL treatment showed behavioural benefits exclusively in control mice as the
Control High Dose exoCAT-SKL group performed better during the learning period in both
latency and distance travelled compared to the Control Empty group (Figure 9, Figure 10). Similar
exoCAT-SKL induced improvements were not demonstrated in 3xTG mice and could be attributed
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to the aggressive phenotype of the 3xTG-AD mice at the age of testing (8.5 months) (Stimmell et
al., no date; Oddo et al., 2003; Sterniczuk et al., 2010). Increased statistical power could also
discern potential differences amongst treatment groups during the probe trial.
The flag trial acted as an important control to ensure that all the mice possessed the basic
abilities to perform the tasks (Vorhees and Williams, 2006; Frame et al., 2019). These abilities
include intact visual acuity, swimming away from the edge of the pool, and climbing onto the exit
platform. The flag trial results did not identify any significant differences between the latency to
the flagged platform among the treatment groups (Figure 12). This indicated that all of the mice
had similar abilities to learn using visuospatial ques, swimming abilities, and motivation to find
the platform. Therefore, any differences in learning and memory retention could be attributed to
differences in genotype or treatment (Frame et al., 2019).

4.5 Off-Target exoCAT-SKL toxicology
Due to the inherent mechanisms of intranasal exoCAT-SKL delivery, off-target tissues
were assessed to ensure the safety of repeated dosing. As with any intranasal drug, ExoCAT-SKL
is likely to be aspirated and deposited into the lung, swallowed into the GI system, and distributed
into the circulatory system (Erdő et al., 2018). Standard investigation of the relative organ weight
of all tissues, including the brain, showed no significant differences in treatment groups and
indicated no chemically induced changes to organs (data not shown). Histopathological assessment
of the highlighted organs (as described in the methods) not only provides evidence that the
intranasal administration of exoCAT-SKL is safe but also sheds light on the therapeutic potential
of exoCAT-SKL for other organ disorders. Although exoCAT-SKL has a high likelihood of
depositing into the lung (Imai et al., 2015), the histopathological assessment of lung tissue
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indicated no perceived abnormalities across all treatments exemplifying the safety of exoCATSKL in terms of preserving the architecture and cellular makeup. In the liver, the absence of
exoCAT-SKL toxicity supports other studies of subcutaneous injections of CAT-SKL being
protective in preclinical models of diabetic retinopathy (Giordano et al., 2015). Assessments of
the spleen across all treatments indicated that mice could tolerate exoCAT-SKL for all treatment
dosages and durations. The absence of histopathological toxicity features in both the small and
large intestines aligns with studies demonstrating protective effects of exogenous catalase in
models of inflammatory bowel disease where exogenous catalase had been shown to decrease
leukocytic ROS production, mucosal damage, and hyperemia (Ruh et al., 2000). Although the
protective effects of exoCAT-SKL on off-target tissue were not investigated in the current study,
the increased peroxisomal specificity of exoCAT-SKL may contribute to its safety. Compared to
exogenous catalase, exoCAT-SKL limits the alterations of necessary redox biology residing in the
cytoplasm or other organelles that maintain physiological functions (Valko et al., 2007; Finkel,
2011; Schieber and Chandel, 2014).

4.6 Limitations and future direction
Two of the biggest limitations of this study are the lack of statistical power for Aim 2 and
the use of mouse models to model human AD. Although it is common practice to use transgenic
mice for preclinical research, the genetic and physiological differences between mice and humans
cause transformative and translational discrepancies in clinical studies (Ellenbroek and Youn,
2016). In addition, the statistical power of Aim 2 of this study was not adequate for evaluating the
effects of exoCAT-SKL on behavioural and histological outcomes.
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This study identified the distribution and safety of intranasal exoCAT-SKL administration;
however, several questions remain regarding the efficacy and mechanisms of CAT-SKL. In
particular, further investigation is required to identify the most effective dosing to prevent AD
pathology in transgenic mice. Indicators of oxidative stress, such as the by-products of lipid
peroxidation in brains of mice treated with and without exoCAT-SKL can be investigated using
MALDI mass spectrometry (Leopold et al., 2018). In vitro experiments can also explore whether
exoCAT-SKL is preferentially internalized within neural cell populations and the extent to which
exoCAT-SKL can reduce ROS and oxidative stress in cell culture models. Future investigation
can also assess the potential of exoCAT-SKL in ameliorating and even reversing AD outcomes in
transgenic mice. The typical diagnosis of AD for most patients occurs following cognitive
impairment and significant pathological load (Petersen, 2009). Giordano et al. have demonstrated
that CAT-SKL can reverse the neurite loss caused by Aβ peptide administration in vitro (Giordano
et al., 2014). Assessing the potential of exoCAT-SKL to reduce and reverse pre-existing
pathological and behavioural correlates will increase its practicality.
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Section 5: CONCLUSION
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Developing potential therapeutic drugs for nervous system disorders such as AD must
consider the disease's complex and debatable pathophysiology. This study has developed methods
to test the safety, biodistribution, and therapeutic potential of a new drug and delivery mechanism,
exoCAT-SKL. Results from the current investigation have provided further evidence that
exosomes can act as carriers of recombinant proteins as well as other potential therapeutic proteins.
The innate ability of exosomes to penetrate the BBB increases its potential in treating
neurodegenerative diseases. Furthermore, the peroxisome targeting ability of CAT-SKL allows for
Control of ROS and oxidative stress at the site of production.
CAT-SKL is a powerful antioxidant; however, its safety in the brain had never been
investigated until now. A critical part of the risk assessment associated with exoCAT-SKL was
assessing its toxicologic effects. Histopathology used in this study did not distinguish exoCATSKL induced abnormalities from normal histological variations. Analysis of brain tissue
determined no features of toxicity such as necrosis, fibrosis, inflammation, and growth
disturbances (i.e. neoplasia, hyperplasia). Off-target toxicity analysis also did not present risks
associated with short-term and long-term intranasal administration of exoCAT-SKL.
AD is strongly tied to oxidative stress, lipid peroxidation, increased inflammatory
mediators, and reduced antioxidant defences (Butterfield et al., 2001; Lull and Block, 2010; Cline
et al., 2018). Although exoCAT-SKL did not demonstrate toxicity in mice, the efficacy of
exoCAT-SKL in preventing AD pathology requires further analysis. Additional investigation is
required to discern whether chronic exoCAT-SKL can reduce ROS and mediate
neuroinflammation responses. Preliminary MWM maze results did not show behavioural
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improvements in exoCAT-SKL treated 3xTD AD mice, but the promise remains in promoting
learning and memory retention in wildtype mice.
This study addressed several barriers of using protein biologics in a therapeutic setting by
answering questions surrounding bioavailability, toxicity, and penetrating the BBB. The use of
exosomes to deliver compounds to cells in need allows for the re-evaluation of other proteinaceous
reagents. In future clinical studies, using a patient's own monocytes as a source of homologous
exosomes could also allow this delivery method to bypass any immune responses. Thus, in an era
of personalized medicine, the use of exosomes will constitute a personalized delivery method that
holds tremendous promise.

73

References
Ali, T. B. et al. (2015) ‘Adverse effects of cholinesterase inhibitors in dementia, according to the
pharmacovigilance databases of the United-States and Canada’, PLoS ONE. Public Library of
Science, 10(12). doi: 10.1371/journal.pone.0144337.
Baes, M. and Aubourg, P. (2009) ‘Peroxisomes, myelination, and axonal integrity in the CNS’,
Neuroscientist, pp. 367–379. doi: 10.1177/1073858409336297.
Bakkour, A. et al. (2013) ‘The effects of aging and Alzheimer’s disease on cerebral cortical
anatomy: Specificity and differential relationships with cognition’, NeuroImage, 76, pp. 332–
344. doi: 10.1016/j.neuroimage.2013.02.059.
Baldassarre, M. et al. (2017) ‘Amyloid β-peptides 1-40 and 1-42 form oligomers with mixed βsheets’, Chemical Science. Royal Society of Chemistry, 8(12), pp. 8247–8254. doi:
10.1039/c7sc01743j.
Ballabh, P., Braun, A. and Nedergaard, M. (2004) ‘The blood-brain barrier: An overview:
Structure, regulation, and clinical implications’, Neurobiology of Disease, pp. 1–13. doi:
10.1016/j.nbd.2003.12.016.
Barage, S. H. and Sonawane, K. D. (2015) ‘Amyloid cascade hypothesis: Pathogenesis and
therapeutic strategies in Alzheimer’s disease’, Neuropeptides. Churchill Livingstone, pp. 1–18.
doi: 10.1016/j.npep.2015.06.008.
Barile, L. and Vassalli, G. (2017) ‘Exosomes: Therapy delivery tools and biomarkers of
diseases’, Pharmacology and Therapeutics. Elsevier Inc., pp. 63–78. doi:
10.1016/j.pharmthera.2017.02.020.

74

Belfiore, R. et al. (2019) ‘Temporal and regional progression of Alzheimer’s disease-like
pathology in 3xTg-AD mice’, Aging Cell. Blackwell Publishing Ltd, 18(1). doi:
10.1111/acel.12873.
Berger, J. et al. (2016) ‘Peroxisomes in brain development and function’, Biochimica et
Biophysica Acta - Molecular Cell Research. Elsevier B.V., 1863(5), pp. 934–955. doi:
10.1016/j.bbamcr.2015.12.005.
Betzer, O. et al. (2017) ‘In Vivo Neuroimaging of Exosomes Using Gold Nanoparticles’, ACS
Nano. doi: 10.1021/acsnano.7b04495.
Bhadbhade, A. and Cheng, D. W. (2012) ‘Amyloid Precursor Protein Processing in Alzheimer’s
Disease’, Iranian Journal of Child Neurology. NIH Public Access, pp. 1–4. doi:
10.1146/annurev-neuro-061010-113613.
Bolmont, T. et al. (2008) ‘Dynamics of the microglial/amyloid interaction indicate a role in
plaque maintenance’, Journal of Neuroscience. Society for Neuroscience, 28(16), pp. 4283–
4292. doi: 10.1523/JNEUROSCI.4814-07.2008.
Bonekamp, N. A. et al. (2009) ‘Reactive oxygen species and peroxisomes: Struggling for
balance’, BioFactors, pp. 346–355. doi: 10.1002/biof.48.
Boveris, A. and Cadenas, E. (2001) ‘Mitochondrial Production of Hydrogen Peroxide Regulation
by Nitric Oxide and the Role of Ubisemiquinone’, IUBMB Life. Wiley, 50(4), pp. 245–250. doi:
10.1080/713803732.
Bregman, C. L. et al. (2003) ‘Recommended Tissue List for Histopathologic Examination in
Repeat-Dose Toxicity and Carcinogenicity Studies: A Proposal of the Society of Toxicologic
Pathology (STP)’, Toxicologic Pathology. doi: 10.1080/01926230390183751.
Bromley-Brits, K., Deng, Y. and Song, W. (2011) ‘Morris Water Maze test for learning and

75

memory deficits in Alzheimer’s disease model mice’, Journal of Visualized Experiments. Journal
of Visualized Experiments, (53). doi: 10.3791/2920.
Brookmeyer, R. et al. (2007) ‘Forecasting the global burden of Alzheimer’s disease’,
Alzheimer’s and Dementia, 3(3), pp. 186–191. doi: 10.1016/j.jalz.2007.04.381.
Butterfield, D. A. et al. (2001) ‘Evidence of oxidative damage in Alzheimer’s disease brain:
Central role for amyloid β-peptide’, Trends in Molecular Medicine, pp. 548–554. doi:
10.1016/S1471-4914(01)02173-6.
Cadet, J. and Richard Wagner, J. (2013) ‘DNA base damage by reactive oxygen species,
oxidizing agents, and UV radiation’, Cold Spring Harbor Perspectives in Biology. Cold Spring
Harbor Laboratory Press, 5(2). doi: 10.1101/cshperspect.a012559.
Chambers, L. W., Bancej, C. and Mcdowell, I. (no date) The Alzheimer Society of Canada in
collaboration with the Prevalence and Monetary Costs of Dementia in Canada PoPulation
HealtH exPert Panel. Available at: www.alzheimer.ca (Accessed: 19 April 2020).
Cheignon, C. et al. (2018) ‘Oxidative stress and the amyloid beta peptide in Alzheimer’s
disease’, Redox Biology. Elsevier B.V., pp. 450–464. doi: 10.1016/j.redox.2017.10.014.
Chow, V. W. et al. (2010) ‘An overview of APP processing enzymes and products.’,
Neuromolecular medicine. NIH Public Access, pp. 1–12. doi: 10.1007/s12017-009-8104-z.
Cipolla, C. M. and Lodhi, I. J. (2017) ‘Peroxisomal Dysfunction in Age-Related Diseases’,
Trends in Endocrinology and Metabolism. doi: 10.1016/j.tem.2016.12.003.
Cline, E. N. et al. (2018) ‘The Amyloid-β Oligomer Hypothesis: Beginning of the Third
Decade’, Journal of Alzheimer’s Disease. IOS Press, pp. S567–S610. doi: 10.3233/JAD-179941.
Cooper, G. M. (2000) ‘Peroxisomes’. Sinauer Associates.
Crowe, T. P. et al. (2018a) ‘Mechanism of intranasal drug delivery directly to the brain’, Life

76

Sciences. doi: 10.1016/j.lfs.2017.12.025.
Crowe, T. P. et al. (2018b) ‘Mechanism of intranasal drug delivery directly to the brain’, Life
Sciences. Elsevier Inc., pp. 44–52. doi: 10.1016/j.lfs.2017.12.025.
Daneman, R. and Prat, A. (2015) ‘The blood–brain barrier’, Cold Spring Harbor Perspectives in
Biology. Cold Spring Harbor Laboratory Press, 7(1). doi: 10.1101/cshperspect.a020412.
Deane, R. et al. (2009) ‘Clearance of amyloid-β peptide across the blood-brain barrier:
Implication for therapies in Alzheimer’s disease’, CNS & neurological disorders drug targets.
NIH Public Access, 8(1), p. 16.
Dharmarajan, T. S. and Gunturu, S. G. (2009) ‘Alzheimer’s disease: A healthcare burden of
epidemic proportion’, American Health and Drug Benefits. Engage Healthcare Communications,
LLC, 2(1), pp. 39–47.
Doens, D. and Fernández, P. L. (2014) ‘Microglia receptors and their implications in the
response to amyloid β for Alzheimer’s disease pathogenesis’, Journal of Neuroinflammation.
BioMed Central Ltd., pp. 1–14. doi: 10.1186/1742-2094-11-48.
Domínguez, L., Sosa-Peinado, A. and Hansberg, W. (2010) ‘Catalase evolved to concentrate
H2O2 at its active site’, Archives of Biochemistry and Biophysics. Academic Press, 500(1), pp.
82–91. doi: 10.1016/j.abb.2010.05.017.
Dröge, W. (2002) ‘Free radicals in the physiological control of cell function’, Physiological
Reviews. doi: 10.1152/physrev.00018.2001.
Dupré-Crochet, S., Erard, M. and Nüβe, O. (2013) ‘ROS production in phagocytes: why, when,
and where?’, Journal of Leukocyte Biology. Wiley, 94(4), pp. 657–670. doi:
10.1189/jlb.1012544.
Elder, G. A. et al. (2010) ‘Presenilin transgenic mice as models of Alzheimer’s disease’, Brain

77

Structure and Function. NIH Public Access, pp. 127–143. doi: 10.1007/s00429-009-0227-3.
Ellenbroek, B. and Youn, J. (2016) ‘Rodent models in neuroscience research: is it a rat race?’,
Disease Models & Mechanisms. doi: 10.1242/dmm.026120.
Erdő, F. et al. (2018) ‘Evaluation of intranasal delivery route of drug administration for brain
targeting’, Brain Research Bulletin. doi: 10.1016/j.brainresbull.2018.10.009.
Fanelli, F. et al. (2013) ‘Age-dependent roles of peroxisomes in the hippocampus of a transgenic
mouse model of Alzheimer’s disease’, Molecular Neurodegeneration. BioMed Central Ltd.,
8(1), p. 8. doi: 10.1186/1750-1326-8-8.
Fernandez, C. G. et al. (2019) ‘The role of apoE4 in disrupting the homeostatic functions of
astrocytes and microglia in aging and Alzheimer’s disease’, Frontiers in Aging Neuroscience.
Frontiers Media S.A., 10(FEB). doi: 10.3389/fnagi.2019.00014.
Fiebich, B. L. et al. (2018) ‘Role of microglia TLRs in neurodegeneration’, Frontiers in Cellular
Neuroscience. Frontiers Media S.A., 12. doi: 10.3389/fncel.2018.00329.
Finkel, T. (2011) ‘Signal transduction by reactive oxygen species’, Journal of Cell Biology. doi:
10.1083/jcb.201102095.
Förstl, H. and Kurz, A. (1999) ‘Clinical features of Alzheimer’s disease’, European Archives of
Psychiatry and Clinical Neuroscience. Springer Verlag, pp. 288–290. doi:
10.1007/s004060050101.
Frame, A. et al. (2019) ‘Simple Protocol for Distinguishing Drug-induced Effects on Spatial
Memory Acquisition, Consolidation and Retrieval in Mice Using the Morris Water Maze’, BioProtocol, 9(18), pp. 1–19. doi: 10.21769/bioprotoc.3376.
Fransen, M. et al. (2012) ‘Role of peroxisomes in ROS/RNS-metabolism: Implications for
human disease’, Biochimica et Biophysica Acta - Molecular Basis of Disease. Elsevier, pp.

78

1363–1373. doi: 10.1016/j.bbadis.2011.12.001.
Giménez-Llort, L. et al. (2013) ‘Early intervention in the 3xTg-AD mice with an amyloid βantibody fragment ameliorates first hallmarks of alzheimer disease’, mAbs. Landes Bioscience,
5(5), pp. 665–864. doi: 10.4161/mabs.25424.
Giordano, C. R. et al. (2014) ‘Amyloid-beta neuroprotection mediated by a targeted antioxidant’,
Scientific Reports. doi: 10.1038/srep04983.
Giordano, C. R. et al. (2015) ‘Catalase therapy corrects oxidative stress-induced
pathophysiology in incipient diabetic retinopathy’, Investigative Ophthalmology and Visual
Science. Association for Research in Vision and Ophthalmology Inc., 56(5), pp. 3095–3102. doi:
10.1167/iovs.14-16194.
Goedert, M. (2005) ‘Tau gene mutations and their effects’, Movement Disorders. doi:
10.1002/mds.20539.
Grimm, M. O. W. et al. (2013) ‘Neprilysin and Aβ clearance: Impact of the APP intracellular
domain in NEP regulation and implications in Alzheimer’s disease’, Frontiers in Aging
Neuroscience. Frontiers Media SA. doi: 10.3389/fnagi.2013.00098.
Groeger, G., Quiney, C. and Cotter, T. G. (2009) ‘Hydrogen peroxide as a cell-survival signaling
molecule’, Antioxidants and Redox Signaling, pp. 2655–2671. doi: 10.1089/ars.2009.2728.
Guerreiro, R. and Bras, J. (2015) ‘The age factor in Alzheimer’s disease’, Genome Medicine.
BioMed Central Ltd., 7(1), pp. 1–3. doi: 10.1186/s13073-015-0232-5.
Ha, D., Yang, N. and Nadithe, V. (2016) ‘Exosomes as therapeutic drug carriers and delivery
vehicles across biological membranes: current perspectives and future challenges’, Acta
Pharmaceutica Sinica B. doi: 10.1016/j.apsb.2016.02.001.
Haass, C. et al. (1995) ‘The Swedish mutation causes early-onset Alzheimer’s disease by β-

79

secretase cleavage within the secretory pathway’, Nature Medicine, 1(12), pp. 1291–1296. doi:
10.1038/nm1295-1291.
Hall, A. M. and Roberson, E. D. (2012) ‘Mouse models of Alzheimer’s disease’, Brain Research
Bulletin. NIH Public Access, pp. 3–12. doi: 10.1016/j.brainresbull.2011.11.017.
Halliday, G. (2017) ‘Pathology and hippocampal atrophy in Alzheimer’s disease’, The Lancet
Neurology. Lancet Publishing Group, pp. 862–864. doi: 10.1016/S1474-4422(17)30343-5.
Haney, M. J. et al. (2015) ‘Exosomes as drug delivery vehicles for Parkinson’s disease therapy’,
Journal of Controlled Release. doi: 10.1016/j.jconrel.2015.03.033.
Hansson, O. et al. (2019) ‘Advantages and disadvantages of the use of the CSF Amyloid β (Aβ)
42/40 ratio in the diagnosis of Alzheimer’s Disease’, Alzheimer’s Research and Therapy.
BioMed Central Ltd., pp. 1–15. doi: 10.1186/s13195-019-0485-0.
Hardy, J. and Allsop, D. (1991) ‘Amyloid deposition as the central event in the aetiology of
Alzheimer’s disease’, Trends in Pharmacological Sciences, pp. 383–388. doi: 10.1016/01656147(91)90609-V.
Hardy, J. and Higgins, G. (1992) ‘Alzheimer’s disease: the amyloid cascade hypothesis’,
Science, 256(5054), pp. 184–185. doi: 10.1126/science.1566067.
Haslund-Vinding, J. et al. (2017) ‘NADPH oxidases in oxidant production by microglia:
activating receptors, pharmacology and association with disease’, British Journal of
Pharmacology. John Wiley and Sons Inc., pp. 1733–1749. doi: 10.1111/bph.13425.
Hemonnot, A. L. et al. (2019) ‘Microglia in Alzheimer disease: Well-known targets and new
opportunities’, Frontiers in Cellular and Infection Microbiology. Frontiers Media S.A., p. 233.
doi: 10.3389/fnagi.2019.00233.
Hensley, K. (2010) ‘Neuroinflammation in Alzheimer’s disease: Mechanisms, pathologic

80

consequences, and potential for therapeutic manipulation’, Journal of Alzheimer’s Disease. IOS
Press, pp. 1–14. doi: 10.3233/JAD-2010-1414.
Huang, X. et al. (1999) ‘Cu(II) potentiation of Alzheimer aβ neurotoxicity. Correlation with cellfree hydrogen peroxide production and metal reduction’, Journal of Biological Chemistry. doi:
10.1074/jbc.274.52.37111.
Huang, Y. and Mahley, R. W. (2014) ‘Apolipoprotein E: Structure and function in lipid
metabolism, neurobiology, and Alzheimer’s diseases’, Neurobiology of Disease. Academic Press
Inc., pp. 3–12. doi: 10.1016/j.nbd.2014.08.025.
Humbert, I. A. et al. (2010) ‘Early deficits in cortical control of swallowing in Alzheimer’s
disease’, Journal of Alzheimer’s Disease. IOS Press, 19(4), pp. 1185–1197. doi: 10.3233/JAD2010-1316.
Imai, T. et al. (2015) ‘Macrophage-dependent clearance of systemically administered B16BL6derived exosomes from the blood circulation in mice’, Journal of Extracellular Vesicles. doi:
10.3402/jev.v4.26238.
Imai, Y. et al. (1996) ‘A novel gene iba1 in the major histocompatibility complex class III region
encoding an EF hand protein expressed in a monocytic lineage’, Biochemical and Biophysical
Research Communications. Academic Press Inc., 224(3), pp. 855–862. doi:
10.1006/bbrc.1996.1112.
International, D. (no date) World Alzheimer Report 2019: Attitudes to dementia; World
Alzheimer Report 2019: Attitudes to dementia. Available at: www.daviddesigns.co.uk (Accessed:
19 April 2020).
Iqbal, K. et al. (2010) ‘Tau in Alzheimer Disease and Related Tauopathies’, Current Alzheimer
Research. Bentham Science Publishers Ltd., 7(8), pp. 656–664. doi:

81

10.2174/156720510793611592.
Iraci, N. et al. (2016) ‘Focus on extracellular vesicles: Physiological role and signalling
properties of extracellular membrane vesicles’, International Journal of Molecular Sciences. doi:
10.3390/ijms17020171.
Jiang, T. et al. (2013) ‘Epidemiology and etiology of Alzheimer’s disease: from genetic to nongenetic factors’, Current Alzheimer Research. doi: 10.2174/15672050113109990155.
Jiang, X. C. and Gao, J. Q. (2017) ‘Exosomes as novel bio-carriers for gene and drug delivery’,
International Journal of Pharmaceutics. doi: 10.1016/j.ijpharm.2017.02.038.
Kelleher, R. J. and Shen, J. (2017) ‘Presenilin-1 mutations and Alzheimer’s disease’,
Proceedings of the National Academy of Sciences of the United States of America. National
Academy of Sciences, pp. 629–631. doi: 10.1073/pnas.1619574114.
Kim, M. S. et al. (2016) ‘Development of exosome-encapsulated paclitaxel to overcome MDR in
cancer cells’, Nanomedicine: Nanotechnology, Biology, and Medicine. Elsevier Inc., 12(3), pp.
655–664. doi: 10.1016/j.nano.2015.10.012.
Koca, E., Taşkapilioğlu, Ö. and Bakar, M. (2017) ‘Caregiver burden in different stages of
Alzheimer’s disease’, Noropsikiyatri Arsivi. Turkish Neuropsychiatric Society, pp. 82–86. doi:
10.5152/npa.2017.11304.
Koepke, J. I. et al. (2007) ‘Restoration of peroxisomal catalase import in a model of human
cellular aging’, Traffic. doi: 10.1111/j.1600-0854.2007.00633.x.
Koepke, J. I. et al. (2008) ‘Progeric effects of catalase inactivation in human cells’, Toxicology
and Applied Pharmacology. Academic Press, 232(1), pp. 99–108. doi:
10.1016/j.taap.2008.06.004.
Lai, C. P. et al. (2014) ‘Dynamic biodistribution of extracellular vesicles in vivo using a

82

multimodal imaging reporter’, ACS Nano. doi: 10.1021/nn404945r.
Lee, K. Y. et al. (2017) ‘Age-related change of Iba-1 immunoreactivity in the adult and aged
gerbil spinal cord’, Anatomy and Cell Biology. Korean Association of Anatomists, 50(2), pp.
135–142. doi: 10.5115/acb.2017.50.2.135.
Lehmann, S. et al. (2018) ‘Relevance of Aβ42/40 ratio for detection of Alzheimer disease
pathology in clinical routine: The PLMR scale’, Frontiers in Aging Neuroscience. Frontiers
Media S.A., 10(MAY). doi: 10.3389/fnagi.2018.00138.
Leopold, J. et al. (2018) ‘Recent developments of useful MALDI matrices for the mass
spectrometric characterization of lipids’, Biomolecules. MDPI AG. doi: 10.3390/biom8040173.
Li, X. et al. (2017) ‘Nano carriers for drug transport across the blood–brain barrier’, Journal of
Drug Targeting. doi: 10.1080/1061186X.2016.1184272.
Liguori, I. et al. (2018) ‘Oxidative stress, aging, and diseases’, Clinical Interventions in Aging.
Dove Medical Press Ltd., pp. 757–772. doi: 10.2147/CIA.S158513.
Liu, S. et al. (2012) ‘The Role of Pericytes in Blood-Brain Barrier Function and Stroke’, Current
Pharmaceutical Design. Bentham Science Publishers Ltd., 18(25), pp. 3653–3662. doi:
10.2174/138161212802002706.
Luan, X. et al. (2017) ‘Engineering exosomes as refined biological nanoplatforms for drug
delivery’, Acta Pharmacologica Sinica. Nature Publishing Group, pp. 754–763. doi:
10.1038/aps.2017.12.
Luissint, A. C. et al. (2012) ‘Tight junctions at the blood brain barrier: Physiological architecture
and disease-associated dysregulation’, Fluids and Barriers of the CNS. BioMed Central, p. 23.
doi: 10.1186/2045-8118-9-23.
Lull, M. E. and Block, M. L. (2010) ‘Microglial Activation and Chronic Neurodegeneration’,

83

Neurotherapeutics. Springer, 7(4), pp. 354–365. doi: 10.1016/j.nurt.2010.05.014.
Macleod, R. et al. (2015) ‘The role and therapeutic targeting of α-, β-and γ-secretase in
Alzheimer’s disease’, Future Science OA. Future Medicine Ltd. doi: 10.4155/fso.15.9.
Majerova, P. et al. (2014) ‘Microglia display modest phagocytic capacity for extracellular tau
oligomers’, Journal of Neuroinflammation. BioMed Central Ltd., 11(1), p. 161. doi:
10.1186/s12974-014-0161-z.
Manoharan, S. et al. (2016) ‘The Role of Reactive Oxygen Species in the Pathogenesis of
Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review’,
Oxidative Medicine and Cellular Longevity. doi: 10.1155/2016/8590578.
Margolis, L. and Sadovsky, Y. (2019) ‘The biology of extracellular vesicles: The known
unknowns’, PLoS Biology. Public Library of Science, 17(7). doi: 10.1371/journal.pbio.3000363.
Matveychuk, D. et al. (2011) ‘Reactive Aldehydes and Neurodegenerative Disorders’, Clinical
Psychopharmacology, 21(4). doi: 10.5455/bcp.19691231040000.
McKelvey, K. J. et al. (2015) ‘Exosomes: Mechanisms of Uptake’, Journal of Circulating
Biomarkers. SAGE Publications Ltd. doi: 10.5772/61186.
Mehta, D. et al. (2017) ‘Why do trials for Alzheimer’s disease drugs keep failing? A
discontinued drug perspective for 2010-2015’, Expert Opinion on Investigational Drugs. Taylor
and Francis Ltd, 26(6), pp. 735–739. doi: 10.1080/13543784.2017.1323868.
Michaelson, D. M. (2014) ‘APOE ε4: The most prevalent yet understudied risk factor for
Alzheimer’s disease’, Alzheimer’s and Dementia. Elsevier Inc., pp. 861–868. doi:
10.1016/j.jalz.2014.06.015.
Moosmann, B. and Behl, C. (2002) ‘Antioxidants as treatment for neurodegenerative disorders’,
Expert Opinion on Investigational Drugs, pp. 1407–1435. doi: 10.1517/13543784.11.10.1407.

84

Morris, R. (1984) ‘Developments of a water-maze procedure for studying spatial learning in the
rat’, Journal of Neuroscience Methods. Elsevier, 11(1), pp. 47–60. doi: 10.1016/01650270(84)90007-4.
Mufson, E. J. et al. (2008) ‘Cholinergic system during the progression of Alzheimer’s disease:
Therapeutic implications’, Expert Review of Neurotherapeutics. NIH Public Access, pp. 1703–
1718. doi: 10.1586/14737175.8.11.1703.
Mylonas, C. and Kouretas, D. (1999) ‘Lipid peroxidation and tissue damage’, In Vivo, pp. 295–
309.
Nell, H. J. et al. (2017) ‘Targeted Antioxidant, Catalase–SKL, Reduces Beta-Amyloid Toxicity
in the Rat Brain’, Brain Pathology. doi: 10.1111/bpa.12368.
10.1111/bpa.12368.
Neugroschl, J. and Wang, S. (2011) ‘Alzheimer’s disease: Diagnosis and treatment across the
spectrum of disease severity’, Mount Sinai Journal of Medicine. NIH Public Access, pp. 596–
612. doi: 10.1002/msj.20279.
Oddo, S. et al. (2003) ‘Triple-transgenic model of Alzheimer’s Disease with plaques and tangles:
Intracellular Aβ and synaptic dysfunction’, Neuron. Cell Press, 39(3), pp. 409–421. doi:
10.1016/S0896-6273(03)00434-3.
Olivares, D. et al. (2013) ‘N-Methyl D-Aspartate (NMDA) Receptor Antagonists and
Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease’,
Current Alzheimer Research. Bentham Science Publishers Ltd., 9(6), pp. 746–758. doi:
10.2174/156720512801322564.
Padurariu, M. et al. (2012) ‘Hippocampal neuronal loss in the CA1 and CA3 areas of
Alzheimer’s disease patients’, Psychiatria Danubina, 24(2), pp. 152–158.

85

Pascucci, L. et al. (2014) ‘Paclitaxel is incorporated by mesenchymal stromal cells and released
in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery’, Journal of
Controlled Release. Elsevier, 192, pp. 262–270. doi: 10.1016/j.jconrel.2014.07.042.
Perl, D. P. (2010) ‘Neuropathology of Alzheimer’s disease’, Mount Sinai Journal of Medicine.
NIH Public Access, pp. 32–42. doi: 10.1002/msj.20157.
Perlman, R. L. (2016) ‘Mouse models of human disease An evolutionary perspective’, Evolution,
pp. 170–176. doi: 10.1093/emph/eow014.
Petersen, R. C. (2009) ‘Early diagnosis of Alzheimer’s disease: is MCI too late?’, Current
Alzheimer research. NIH Public Access, 6(4), pp. 324–30. doi: 10.2174/156720509788929237.
Pham-Huy, L. A., He, H. and Pham-Huy, C. (2008) ‘Free radicals, antioxidants in disease and
health’, International Journal of Biomedical Science. Master Publishing Group, pp. 89–96.
Pharmaceu Sci, G. J., Shah, D. and Shao, J. (2017) ‘Nasal Delivery of Proteins and Peptides’, 1.
doi: 10.19080/GJPPS.2017.01.555569.
Piaceri, I., Nacmias, B. and Sorbi, S. (2013) ‘Genetics of familial and sporadic Alzheimer’s
disease.’, Frontiers in bioscience (Elite edition). doi: 10.2741/E605.
Pomatto, M. A. C. et al. (2019) ‘Improved Loading of Plasma-Derived Extracellular Vesicles to
Encapsulate Antitumor miRNAs’, Molecular Therapy - Methods and Clinical Development. Cell
Press, 13, pp. 133–144. doi: 10.1016/j.omtm.2019.01.001.
Praticò, D. et al. (2001) ‘Increased lipid peroxidation precedes amyloid plaque formation in an
animal model of alzheimer amyloidosis’, Journal of Neuroscience, 21(12), pp. 4183–4187. doi:
10.1523/jneurosci.21-12-04183.2001.
Preventing Alzheimer’s Disease: What Do We Know? (no date). Available at:
https://www.nia.nih.gov/health/preventing-alzheimers-disease-what-do-we-know (Accessed: 20

86

April 2020).
Price, M., Terlecky, S. R. and Kessel, D. (2009) ‘A role for hydrogen peroxide in the proapoptotic effects of photodynamic therapy’, Photochemistry and Photobiology. doi:
10.1111/j.1751-1097.2009.00589.x.
Puig, K. L. and Combs, C. K. (2013) ‘Expression and function of APP and its metabolites
outside the central nervous system’, Experimental Gerontology. NIH Public Access, pp. 608–
611. doi: 10.1016/j.exger.2012.07.009.
Qiu, T. et al. (2015) ‘Aβ42 and Aβ40: similarities and differences’, Journal of Peptide Science.
John Wiley and Sons Ltd, 21(7), pp. 522–529. doi: 10.1002/psc.2789.
Qu, M. et al. (2018) ‘Dopamine-loaded blood exosomes targeted to brain for better treatment of
Parkinson’s disease’, Journal of Controlled Release. doi: 10.1016/j.jconrel.2018.08.035.
Raj, D. et al. (2017) ‘Increased white matter inflammation in aging- and Alzheimer’s disease
brain’, Frontiers in Molecular Neuroscience, 10(206), pp. 1–18. doi: 10.3389/fnmol.2017.00206.
Raskin, J. et al. (2015) ‘Neurobiology of Alzheimer’s Disease: Integrated Molecular,
Physiological, Anatomical, Biomarker, and Cognitive Dimensions’, Current Alzheimer
Research. Bentham Science Publishers Ltd., 12(8), pp. 712–722. doi:
10.2174/1567205012666150701103107.
Ray, P. D., Huang, B. W. and Tsuji, Y. (2012) ‘Reactive oxygen species (ROS) homeostasis and
redox regulation in cellular signaling’, Cellular Signalling. NIH Public Access, pp. 981–990.
doi: 10.1016/j.cellsig.2012.01.008.
Resende, R. et al. (2008) ‘Brain oxidative stress in a triple-transgenic mouse model of Alzheimer
disease’, Free Radical Biology and Medicine. Pergamon, 44(12), pp. 2051–2057. doi:
10.1016/j.freeradbiomed.2008.03.012.

87

Ricciarelli, R. and Fedele, E. (2017) ‘The Amyloid Cascade Hypothesis in Alzheimer’s Disease:
It’s Time to Change Our Mind’, Current Neuropharmacology. Bentham Science Publishers Ltd.,
15(6), p. 926. doi: 10.2174/1570159x15666170116143743.
Ruh, J. et al. (2000) ‘Effects of hydrogen peroxide scavenger Catalase on villous
microcirculation in the rat small intestine in a model of inflammatory bowel disease’,
Microvascular Research. doi: 10.1006/mvre.1999.2201.
Safieh, M., Korczyn, A. D. and Michaelson, D. M. (2019) ‘ApoE4: an emerging therapeutic
target for Alzheimer’s disease’, BMC Medicine. BioMed Central Ltd., 17(1), pp. 1–17. doi:
10.1186/s12916-019-1299-4.
Saito, T. and Saido, T. C. (2018) ‘Neuroinflammation in mouse models of Alzheimer’s disease’,
Clinical and Experimental Neuroimmunology. Wiley-Blackwell, pp. 211–218. doi:
10.1111/cen3.12475.
Schieber, M. and Chandel, N. S. (2014) ‘ROS function in redox signaling and oxidative stress’,
Current Biology. doi: 10.1016/j.cub.2014.03.034.
Schrader, M. and Fahimi, H. D. (2006) ‘Peroxisomes and oxidative stress’, Biochimica et
Biophysica Acta - Molecular Cell Research, pp. 1755–1766. doi: 10.1016/j.bbamcr.2006.09.006.
Scott, C. C., Vacca, F. and Gruenberg, J. (2014) ‘Endosome maturation, transport and functions’,
Seminars in Cell and Developmental Biology. Elsevier Ltd, pp. 2–10. doi:
10.1016/j.semcdb.2014.03.034.
Selkoe, D. J. (1991) ‘The molecular pathology of Alzheimer’s disease’, Neuron, pp. 487–498.
doi: 10.1016/0896-6273(91)90052-2.
Sengupta, U., Nilson, A. N. and Kayed, R. (2016) ‘The Role of Amyloid-β Oligomers in
Toxicity, Propagation, and Immunotherapy’, EBioMedicine. Elsevier B.V., pp. 42–49. doi:

88

10.1016/j.ebiom.2016.03.035.
Serlin, Y. et al. (2015) ‘Anatomy and physiology of the blood-brain barrier’, Seminars in Cell
and Developmental Biology. Academic Press, pp. 2–6. doi: 10.1016/j.semcdb.2015.01.002.
Sharman, E. H. (2016) ‘Reactive Oxygen Species and Protein Oxidation in Neurodegenerative
Disease’, in. Springer, Cham, pp. 199–212. doi: 10.1007/978-3-319-33486-8_11.
Sheikh, F. G. et al. (1998) ‘Abnormality in catalase import into peroxisomes leads to severe
neurological disorder’, Proceedings of the National Academy of Sciences of the United States of
America. National Academy of Sciences, 95(6), pp. 2961–2966. doi: 10.1073/pnas.95.6.2961.
Sterniczuk, R. et al. (2010) ‘Characterization of the 3xTg-AD mouse model of Alzheimer’s
disease: Part 2. Behavioral and cognitive changes’, Brain Research, 1348, pp. 149–155. doi:
10.1016/j.brainres.2010.06.011.
Stimmell, A. C. et al. (no date) ‘Impaired Spatial Reorientation in the 3xTg-AD Mouse Model of
Alzheimer’s Disease’. doi: 10.1101/258616.
Storrie, B. and Madden, E. A. (1990) ‘Isolation of subcellular organelles’, Methods in
Enzymology. Academic Press, 182(C), pp. 203–225. doi: 10.1016/0076-6879(90)82018-W.
Stover, K. R. et al. (2015) ‘Early detection of cognitive deficits in the 3xTg-AD mouse model of
Alzheimer’s disease’, Behavioural Brain Research. Elsevier, 289, pp. 29–38. doi:
10.1016/j.bbr.2015.04.012.
Su, B. et al. (2008) ‘Oxidative Stress Signaling in Alzheimers Disease’, Current Alzheimer
Research. Bentham Science Publishers Ltd., 5(6), pp. 525–532. doi:
10.2174/156720508786898451.
Sultana, R., Perluigi, M. and Butterfield, D. A. (2013) ‘Lipid peroxidation triggers
neurodegeneration: A redox proteomics view into the Alzheimer disease brain’, Free Radical

89

Biology and Medicine. Elsevier Inc., pp. 157–169. doi: 10.1016/j.freeradbiomed.2012.09.027.
Sweeney, M. D., Sagare, A. P. and Zlokovic, B. V. (2018) ‘Blood-brain barrier breakdown in
Alzheimer disease and other neurodegenerative disorders’, Nature Reviews Neurology. Nature
Publishing Group, pp. 133–150. doi: 10.1038/nrneurol.2017.188.
Szatanek, R. et al. (2015) ‘Isolation of extracellular vesicles: Determining the correct approach
(review)’, International Journal of Molecular Medicine. Spandidos Publications, pp. 11–17. doi:
10.3892/ijmm.2015.2194.
Terlecky, S. R., Koepke, J. I. and Walton, P. A. (2006) ‘Peroxisomes and aging’, Biochimica et
Biophysica Acta - Molecular Cell Research. NIH Public Access, pp. 1749–1754. doi:
10.1016/j.bbamcr.2006.08.017.
Tetta, C. et al. (2013) ‘Extracellular vesicles as an emerging mechanism of cell-to-cell
communication’, Endocrine. Springer, pp. 11–19. doi: 10.1007/s12020-012-9839-0.
Théry, C. et al. (2006) ‘Isolation and Characterization of Exosomes from Cell Culture
Supernatants and Biological Fluids’, Current Protocols in Cell Biology. doi:
10.1002/0471143030.cb0322s30.
Valko, M. et al. (2007) ‘Free radicals and antioxidants in normal physiological functions and
human disease’, International Journal of Biochemistry and Cell Biology. doi:
10.1016/j.biocel.2006.07.001.
Vanitallie, T. B. (2013) ‘Preclinical sporadic Alzheimer’s disease: Target for personalized
diagnosis and preventive intervention’, Metabolism: Clinical and Experimental. doi:
10.1016/j.metabol.2012.08.024.
Verma, M., Vats, A. and Taneja, V. (2015) ‘Toxic species in amyloid disorders: Oligomers or
mature fibrils’, Annals of Indian Academy of Neurology. Medknow Publications, pp. 138–145.

90

doi: 10.4103/0972-2327.144284.
Vorhees, C. V. and Williams, M. T. (2006) ‘Morris water maze: Procedures for assessing spatial
and related forms of learning and memory’, Nature Protocols. NIH Public Access, 1(2), pp. 848–
858. doi: 10.1038/nprot.2006.116.
Walton, P. A. and Pizzitelli, M. (2012) ‘Effects of peroxisomal catalase inhibition on
mitochondrial function’, Frontiers in Physiology. Frontiers Media SA, 3 APR. doi:
10.3389/fphys.2012.00108.
Wanders, R. J. A., Waterham, H. R. and Ferdinandusse, S. (2016) ‘Metabolic interplay between
peroxisomes and other subcellular organelles including mitochondria and the endoplasmic
reticulum’, Frontiers in Cell and Developmental Biology. Frontiers Media S.A. doi:
10.3389/fcell.2015.00083.
Wang, W. Y. et al. (2015) ‘Role of pro-inflammatory cytokines released from microglia in
Alzheimer’s disease’, Annals of Translational Medicine. AME Publishing Company. doi:
10.3978/j.issn.2305-5839.2015.03.49.
Wang, X. et al. (2014) ‘Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease’,
Biochimica et Biophysica Acta - Molecular Basis of Disease. doi: 10.1016/j.bbadis.2013.10.015.
Whitwell, J. L. (2010) ‘The protective role of brain size in Alzheimer’s disease’, Expert Review
of Neurotherapeutics. NIH Public Access, pp. 1799–1801. doi: 10.1586/ern.10.168.
Winterbourn, C. C. (1995) ‘Toxicity of iron and hydrogen peroxide: the Fenton reaction’,
Toxicology Letters. Elsevier, 82–83(C), pp. 969–974. doi: 10.1016/0378-4274(95)03532-X.
Xiang, Z. et al. (2006) ‘Microglia activation in the brain as inflammatory biomarker of
Alzheimer’s disease neuropathology and clinical dementia.’, Disease markers, 22, pp. 95–102.
doi: 10.1155/2006/276239.

91

Xie, A. et al. (2014) ‘Shared Mechanisms of Neurodegeneration in Alzheimer’s Disease and
Parkinson’s Disease’, BioMed Research International. Hindawi Limited, 2014. doi:
10.1155/2014/648740.
Yáñez-Mó, M. et al. (2015) ‘Biological properties of extracellular vesicles and their
physiological functions’, Journal of Extracellular Vesicles. doi: 10.3402/jev.v4.27066.
Yang, J. et al. (2017) ‘Histological and anatomical structure of the nasal cavity of Bama
minipigs’. doi: 10.1371/journal.pone.0173902.
Yiannopoulou, K. G. and Papageorgiou, S. G. (2013) ‘Current and future treatments for
Alzheimer’s disease’, Therapeutic Advances in Neurological Disorders. SAGE Publications, pp.
19–33. doi: 10.1177/1756285612461679.
Zanetti, O., Solerte, S. B. and Cantoni, F. (2009) ‘Life expectancy in Alzheimer’s disease (AD).’,
Archives of gerontology and geriatrics, pp. 237–243. doi: 10.1016/j.archger.2009.09.035.
Zhang, Y. et al. (2019) ‘Exosomes: Biogenesis, biologic function and clinical potential’, Cell
and Bioscience. BioMed Central Ltd., pp. 1–18. doi: 10.1186/s13578-019-0282-2.
Zhang, Y. W. et al. (2011) ‘APP processing in Alzheimer’s disease’, Molecular Brain. BioMed
Central, p. 3. doi: 10.1186/1756-6606-4-3.
Zhuang, X. et al. (2011) ‘Treatment of brain inflammatory diseases by delivering exosome
encapsulated anti-inflammatory drugs from the nasal region to the brain’, Molecular Therapy.
Nature Publishing Group, 19(10), pp. 1769–1779. doi: 10.1038/mt.2011.164.
Zuo, L. et al. (2015) ‘Biological and physiological role of reactive oxygen species - the good, the
bad and the ugly’, Acta Physiologica. Blackwell Publishing Ltd, pp. 329–348. doi:
10.1111/apha.12515.

92

Appendix

AUP Number: 2018-068
PI Name: Whitehead, Shawn N
AUP Title: Exosome delivery of biologics to mice Approval Date: 07/01/2018
Official Notice of Animal Care Committee (ACC) Approval:
Your new Animal Use Protocol (AUP) 2018-068:1: entitled " Exosome delivery of biologics to
mice" has been APPROVED by the Animal Care Committee of the University Council on
Animal Care. This approval, although valid for up to four years, is subject to annual Protocol
Renewal.
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee University Council on Animal Care

93

Curriculum Vitae
QINGFAN LIU
HIGHLIGHTS OF QUALIFICATIONS
•
•

•

Western University’s Faculty of Science National Scholarship recipient ($30,000)
• Awarded for outstanding academic performance, achievement in
extracurricular activities and commitment to community service
2019-2020 Canadian Institute of Health Research (CIHR) – Frederick Banting and
Charles Best Canada Graduate Scholarship recipient ($17,500)
• Awarded annually to 14 Master’s students at Western University who
demonstrate high standards of achievement in undergraduate and early
graduate studies
2019 Thales Student Innovation Championships 1st Place Winner ($20,000)
• Awarded to the best innovative solution that solves a theoretical challenge using
artificial intelligence across Canada

EDUCATION
Schulich School of Medicine and Dentistry
London, ON
2020-2024
•
Doctor of Medicine
Schulich School of Medicine and Dentistry
London, ON
2018-2020
•
Master of Science
• Anatomy and Cell Biology
Western University
London, ON
2014-2018
•
Bachelor of Medical Science with Distinction
• Honors Specialization in Interdisciplinary Medical Science, Minor in Mathematics
• 2014-2018 Western University Dean’s Honor List
PUBLICATIONS
•

•
•

A. Levit, S. Cheng, O. Hough, Q. Liu, Y. Agca, C. Agca, V. Hachinski and S. N.
Whitehead. Hypertension and Pathogenic hAPP Independently Induce White Matter
Astrocytosis and Cognitive Impairment in the Rat. Frontiers in Aging Neuroscience
(2020).
N. Ivanova, Q. Liu, C. Agca, Y. Agca, E.G. Noble, S. N. Whitehead and D.F. Cechetto.
White matter inflammation and cognitive function in a co-morbid metabolic syndrome
and prodromal Alzheimer’s disease rat model. Journal of Neuroinflammation (2020).
N. Weishaupt*, Q. Liu*, S. Shin, R. Singh, Y. Agca, C. Agca, V. Hachinski and S. N.
Whitehead. APP21 transgenic rats develop age-dependent cognitive impairment and
microglia within white matter tracts. Journal of Neuroinflammation (2018).
* indicates both authors contributed equally.

94

•

S. Caughlin, J. Hepburn, Q. Liu, L. Wang, K. Yeung, D. Cechetto and S.N. Whitehead.
Chloroquine restores ganglioside homeostasis and improves pathological and behavioral
outcomes post-stroke in the rat. Journal of Molecular Biology (2018)

POSTER PRESENTATIONS
•
•

•
•

Q. Liu, S. Hayes, P. Kiser, S. Selvakumaran, B.L. Allman, P.Walton and S.N.
Whitehead. Evaluating the neuroprotective potential of exosome delivered catalase-SKL
in a pre-clinical model of Alzheimer's disease. Society of Neuroscience, Chicago (2019).
Q. Liu, N. Weishaupt, S. Shin, R. Singh, Y. Agca, C. Agca, V. Hachinski and S.N.
Whitehead. Transgenic rat model of Alzheimer's disease develops deficits in cognition
and widespread neuroinflammation with age. Canadian Association of Neuroscience,
Toronto (2019).
Q. Liu, N. Weishaupt, S. Shin, R. Singh, Y. Agca, C. Agca, V. Hachinski and S.N.
Whitehead. APP21 transgenic rats develop age-dependent cognitive impairment and
microglia within white matter tracts. Experimental Biology, Orlando, Florida (2019).
S. Selvakumaran, S. Hayes, Q. Liu, T. Ni, P.A. Walton, B.L. Allman. Exosome
Packaging of the Targeted Antioxidant CAT-SKL to Protect the Sensory Cells in the
Inner Ear. Experimental Biology, Orlando, Florida (2019).

ORAL PRESENTATIONS
•

Q. Liu, S. Shin, S.N. Whitehead. Characterization of Inflammation and Microglia in a
Rat Model following Ischemic Stroke. Western Student Research Conference, London,
ON (2016).

WORK EXPERIENCE AND COMMUNITY INVOLVEMENT
Vulnerable Brain Laboratory Member
Schulich School of Medicine and Dentistry
London, ON
2012-Current
Stroke, Alzheimer’s Disease, and Dementia Research Assistant
•
Performed perfusions, brain extractions, pathological and histological analysis on both
rats and mice resulting in competency in animal experimentation and wet lab work
•
Coordinated research projects investigating temporal and spatial characterization of brain
inflammation following ischemic stroke resulting in presentation at 2016 Western
Student Research Conference
•
Analyzed rodent neuroanatomy using confocal and fluorescent microscopy and
imaging software identifying pathological and histological abnormalities to produce
figures for publications and poster presentations
•
Investigated white matter inflammation and cognitive impairment in transgenic rats
through Dean Undergraduate Research Opportunities Program (DUROP) resulting in cofirst author publication in Journal of Neuroinflammation
•
Combined 6 years of work experience in research leading to mentorship position and
established foundation to pursue a master’s degree at Western University, Schulich
School of Medicine and Dentistry
Alzheimer’s Disease Stroke, Alzheimer’s Disease, and Dementia Research Mentor
95

•
•

Mentored three laboratory research volunteers in animal handling, microscopy,
immunohistochemistry, amongst other laboratory techniques to develop their
independence to take on individual projects
Designated small research projects for laboratory volunteers and provided ongoing
guidance until completion

Alzheimer’s Society Companion Program Volunteer
Alzheimer Society London and Middlesex London, ON
2018-2020
•
Provided weekly one-on-one visits for companion with mid-stage dementia promoting
socialization and cognitive engagement, over time building a new friendship that
improves the quality of life for the companion and their family
Western University Integrative Neuroscience Teaching Assistant
Western University London, ON
2018-2019
•
Employed as a teaching assistant for the course Integrative Neuroscience designed for
4th year medical science university students
•
Facilitated student learning in the classroom, laboratory and online by guiding
dissections and answering questions
•
Provided technological support to professors and evaluated participation for in-class
students improving grading objectivity and consistency
Western University Anatomy and Cell Biology Graduate Teaching Assistant Steward
Western University London, ON
2018-2019
•
Provided communication link amongst all the Graduate Teaching assistants and PostDoctoral assistants in the department of Anatomy and Cell Biology at Western
University
•
Protected the rights of Graduate Teaching Assistants as bargained for in the Collective
Agreement by the Public Service Alliance of Canada
•
Organized TA Solidarity event for the department to discuss TA rights and resolve
grievances
Western University Dragon Boat Team Dry-land Coach
Western University London, ON
2016-2018
•
Organized fitness regimes for over 120 team members up to four times a week to
gradually build strength and endurance throughout the season
•
Provided in depth instruction and classes on skills related to paddling, strength, and
cardiovascular fitness to ensure members used proper form and trained safely
•
Monitored the performance of each team member to provide individualized
constructive feedback and supported team members in reaching personal goals
•
Competed in regional, provincial, and national level regattas resulting in multiple
Canadian Dragon Boat Championship podium finishes
Western University National Scholarship Mentor Link Program
Western University London, ON
2016-2018
•
Mentored national scholarship recipients year-round by connecting freshman students to
Western University’s social environment and its academic resources to ensure smooth
transitions into university life
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•

Provided one on one orientation of campus and student life for incoming first year
students

Western University Dragon Boat Fundraising Executive
Western University London, ON
2014-2016
•
Coordinated sponsorships from corporate and local companies; fundraised over $1000
through creative and appropriate ideas for the team
•
Designated tasks and provided training to fundraising representatives for effective
communication with corporate sponsors
AWARDS AND DISTINCTIONS
Academic Achievements
•
2019-2020 Canadian Institute of Health Research (CIHR) – Frederick Banting and
Charles Best Canada Graduate Scholarship recipient ($17,500)
• Awarded annually to 14 master’s students at Western University who
demonstrate high standards of achievement in undergraduate and early
graduate studies
•
2019 Ontario Graduate Scholarship ($15,000) *Declined
•
2019 Schulich School of Medicine and Dentistry Dept. Anatomy and Cell Biology
Travel Award
•
2014 Western University Faculty of Science National Scholarship Recipient
($30,000)
• Awarded for outstanding academic performance, achievement in
extracurricular activities and commitment to community service
•
2014-2018 Western University Dean’s Honor List
•
2013 Canadian Senior Mathematics Contest National Honor Roll
•
2013 Fermat Mathematics Contest Canadian Gold Medalist (Perfect Score)
•
2011 Pascal Mathematics Contest Canadian Gold Medalist (Perfect Score)
Extra-Curricular Achievements
•
2018 Thales Student Innovation Championship 1st Place Winner ($20,000)
• Awarded to the best innovative solutions that solves a theoretical challenge using
Artificial Intelligence across Canada
•
2018 Schulich School of Medicine and Dentistry Interdisciplinary Medical Science
Speaker Series Guest Speaker
•
2017 Dean’s Undergraduate Research Opportunities Program Summer Award Recipient
($6,000)
• Awarded to outstanding science undergraduate students to pursue medical research
•
2016 Western Student Research Conference Presentation
• Project Title: Characterization of Microglia following Ischemic Stroke
•
2014 Schulich Leader Scholarship Nominee
Athletic Achievements
•
2019 Owl’s Head Quebec Super Spartan Race Finisher
•
2019 Subaru Triathlon Series Guelph Lake I – “Try a Tri” - Men’s 20-24 Gold Medalist
•
2018 Canadian Dragon Boat Championships University Mixed Division Bronze
Medalists
•
2018 Canadian Dragon Boat Championships U24 Open Division Silver Medalists
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•
•
•
•
•

2018 Toronto International Dragon Boat Festival University Division Finalist
2017 Canadian Dragon Boat Championships University A Division Finalists
2015 Canadian Dragon Boat Championships University Open Division Silver Medalists
2014 Alex Kelman SPECTRA (Sportsmanship, Participation, Excellence,
Character, Teamwork, Respect and Achievement) Award Nominee
2014 Wil Rice and Bill Traut Athletic Award ($2500)
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